US6228575B1 - Chip-based species identification and phenotypic characterization of microorganisms - Google Patents

Chip-based species identification and phenotypic characterization of microorganisms Download PDF

Info

Publication number
US6228575B1
US6228575B1 US08/797,812 US79781297A US6228575B1 US 6228575 B1 US6228575 B1 US 6228575B1 US 79781297 A US79781297 A US 79781297A US 6228575 B1 US6228575 B1 US 6228575B1
Authority
US
United States
Prior art keywords
nucleic acid
hybridization
acid sequence
organism
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/797,812
Other languages
English (en)
Inventor
Thomas R. Gingeras
David Mack
Mark S. Chee
Anthony J. Berno
Lubert Stryer
Ghassan Ghandour
Ching Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymetrix Inc
Original Assignee
Affymetrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymetrix Inc filed Critical Affymetrix Inc
Priority to US08/797,812 priority Critical patent/US6228575B1/en
Assigned to AFFYMETRIX, INC. reassignment AFFYMETRIX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEE, MARK S., MACK, DAVID, BERNO, ANTHONY J., GINGERAS, THOMAS R., STRYER, LUBERT, WANG, CHING, GHANDOUR, GHASSAN
Priority to US09/724,938 priority patent/US6924094B1/en
Publication of US6228575B1 publication Critical patent/US6228575B1/en
Application granted granted Critical
Priority to US11/050,647 priority patent/US7252948B2/en
Priority to US11/255,120 priority patent/US20060177843A1/en
Assigned to GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT reassignment GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT SECURITY AGREEMENT Assignors: AFFYMETRIX, INC.
Assigned to BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT reassignment BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AFFYMETRIX, INC.
Assigned to AFFYMETRIX, INC. reassignment AFFYMETRIX, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Assigned to AFFYMETRIX, INC. reassignment AFFYMETRIX, INC. NOTICE OF RELEASE Assignors: BANK OF AMERICA, N.A.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00497—Features relating to the solid phase supports
    • B01J2219/00527—Sheets
    • B01J2219/00529—DNA chips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00608—DNA chips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00612—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00623—Immobilisation or binding
    • B01J2219/00626—Covalent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Definitions

  • This invention relates to the identification and characterization of microorganisms.
  • Multidrug resistance and human immunodeficiency virus (HIV-1) infections are factors which have had a profound impact on the tuberculosis problem.
  • An increase in the frequency of Mycobacterium tuberculosis strains resistant to one or more anti-mycobacterial agents has been reported, Block, et al., (1994) JAMA 271:665-671.
  • Immunocompromised HIV-1 infected patients not infected with M. tuberculosis are frequently infected with M. avium complex (MAC) or M. avium - M. intracellulare (MAI) complex.
  • MAC M. avium complex
  • MAI M. avium - M. intracellulare
  • Non-tuberculosis mycobacteria commonly associated with HIV-1 infections include M. kansasii, M. xenopi, M. fortuitum, M. avium and M. intracellular, Wolinsky, E., (1992) Clin. Infect. Dis. 15:1-12, Shafer, R. W. and Sierra, M. F. 1992 Clin. Infect. Dis. 15:161-162.
  • cultured mycobacteria can be analyzed by lipid composition, the use of species specific antibodies, species specific DNA or RNA probes and PCR-based sequence analysis of 16S rRNA gene (Schirm, et al. (1995) J. Clin. Microbiol. 33:3221-3224; Kox, et al. (1995) J. Clin. Microbiol. 33:3225-3233) and IS6110 specific repetitive sequence analysis (For a review see, e.g., Small et al., P. M. and van Embden, J. D. A. (1994) Am. Society for Microbiology , pp. 569-582).
  • RNA and DNA 16S rRNA sequences
  • Table 1 lists the M. tuberculosis genes with which when mutated have been shown to confer drug resistance (other genes are known, e.g., the pncA gene).
  • RIF and INH form the backbone of tuberculosis treatment. Detection of RIF resistance in M. tuberculosis is important not only because of its clinical and epidemiological implications but also because it is a marker for the highly threatening multidrug resistant phenotype (Telenti, et al. (1993) The Lancet 341:647-650).
  • decreased sensitivity to RIF is the best understood on a genetic basis.
  • Missense mutations comprise 88% of all known mutations while insertions (3 or 6 bp) and deletions (3, 6 and 9 bp) account for 4% and 8% of the remaining mutations, respectively.
  • insertions 3 or 6 bp
  • deletions 3, 6 and 9 bp
  • Approximately 90% of all RIF resistant tuberculosis isolates have been shown to have mutations in this 81 bp region. The remaining 10% are thought possibly to involve genes other than rpoB.
  • the present invention provides systems, methods, and devices for characterizing and identifying organisms.
  • a method for identifying a genotype of a first organism comprising:
  • Another aspect of the invention provides a method for identifying the genotype and/or phenotype of an organism by comparing a target nucleic acid sequence from a first organism coding for a gene (or its complement) to a reference sequence coding for the same gene (or its complement) from a second organism, the method comprising:
  • a first probe set comprising a plurality of probes, each probe comprising a segment of nucleotides exactly complementary to a subsequence of the reference sequence, the segment including at least one interrogation position complementary to a corresponding nucleotide in the reference sequence;
  • Another aspect of the invention provides a method for identifying the genotype and/or phenotype of an organism by comparing a target nucleic acid sequence from a first organism coding for a gene (or its complement) to a reference sequence coding for the same gene (or its complement) from a second organism, the method comprising:
  • a first probe set comprising a plurality of probes, each probe comprising a segment of nucleotides exactly complementary to a subsequence of the reference sequence, the segment including at least one interrogation position complementary to a corresponding nucleotide in the reference sequence, wherein each interrogation position corresponds to a nucleotide position in the reference or target sequence;
  • Another aspect of the invention provides an array of oligonucleotide probes immobilized on a solid support, the array comprising:
  • a first probe set comprising a plurality of probes, each probe comprising a segment of nucleotides exactly complementary to a subsequence of a reference sequence, the segment including at least one interrogation position complementary to a corresponding nucleotide in the reference sequence;
  • reference sequence is a gene from Mycobacterium tuberculosis.
  • Another aspect of the invention provides a method of identifying the presence of a nucleic acid polymorphism in a patient sample, comprising the steps of:
  • Another aspect of the invention provides a computer program product that identifies the presence of a nucleic acid polymorphism in a patient sample, comprising:
  • Another aspect of the invention provides, in a computer system, a method of assigning an organism to a group, comprising the steps of:
  • each hybridization pattern indicating hybridization of subsequences of the known nucleic acid sequence to subsequences of a reference nucleic acid sequence
  • Another aspect of the invention provides a computer program product that assigns an organism to a group, comprising:
  • each hybridization pattern indicating hybridization of subsequences of the known nucleic acid sequence to subsequences of a reference nucleic acid sequence
  • Another aspect of the invention provides, in a computer system, a method of assigning groups to which organisms belong utilizing a generic probe array, comprising the steps of:
  • hybridization intensities for a plurality of isolates, the hybridization intensities indicating hybridization affinity between the isolate and the generic probe array;
  • Another aspect of the invention provides a computer program product that assigns groups to which organisms belong utilizing a generic probe array, comprising the steps of:
  • FIG. 1 (SEQ ID NO:9): Basic tiling strategy. The figure illustrates the relationship between an interrogation position (I) and a corresponding nucleotide (n) in the reference sequence, and between a probe from the first probe set and corresponding probes from second, third and fourth probe sets.
  • FIG. 2 SEQ ID NOS: 9-10: Segment of complementarity in a probe from the first probe set.
  • FIG. 3 (SEQ ID NOS: 11-23): Incremental succession of probes in a basic tiling strategy.
  • the figure shows four probe sets, each having three probes. Note that each probe differs from its predecessor in the same set by the acquisition of a 5′ nucleotide and the loss of a 3′ nucleotide, as well as in the nucleotide occupying the interrogation position.
  • FIG. 4 Exemplary arrangement of lanes on a chip.
  • the chip shows four probe sets, each having five probes and each having a total of five interrogation positions (I1-I5), one per probe.
  • FIG. 5 Strategies for detecting deletion and insertion mutations. Bases in brackets may or may not be present.
  • FIG. 6 Shows the light directed synthesis of oligonucleotide probes on a substrate.
  • FIG. 7 Shows the synthesis of a combinatorial array all possible tetranucleotide oligomers on a chip.
  • FIG. 8 A schematic diagram of target preparation.
  • FIG. 9 A tiling strategy for sequence determination.
  • FIG. 10 A mismatch profile for an octamer based chip.
  • FIG. 11 A hypothetical six-class tree based classification system. The numbers underneath the terminal nodes are the class assignments as determined by this classifier.
  • FIG. 12 Shared single nucleotide polymorphisms of seven Mycobacterium species.
  • FIG. 13 Unique (species-specific) single nucleotide polymorphisms of seven Mycobacterium species.
  • FIGS. 14 A and 14 B Hybridization patterns and bar code fingerprint representations of seven Mycobacterium species.
  • FIG. 15 Bar code fingerprint representations of seven M. gordonae clinical isolates and the core fingerprint derived therefrom.
  • FIG. 16 A and FIG. 16B Plot of hybridization intensity vs. nucleotide position using M. gordonae as target on an Mycobacterium tuberculosis rpoB chip.
  • the bottom panel shows the sequences of the rpoB genes of M. tuberculosis and M. gordonae with the position of difference outlined in black.
  • FIG. 17 Plot of hybridization intensity vs. nucleotide position using other Mycobacterium species as target on an Mycobacterium tuberculosis rpoB chip.
  • FIG. 18 Plots of hybridization intensity vs. nucleotide position using Mycobacterium species as target on an Mycobacterium tuberculosis rpoB chip overlayed on the corresponding plot for Mycobacterium tuberculosis.
  • FIGS. 19A-19D and FIG. 20 Plots of hybridization intensity vs. nucleotide position of an unknown patient sample compared to plots of known Mycobacterium species as target on an Mycobacterium tuberculosis rpoB chip.
  • FIG. 21 Plots of hybridization intensity vs. nucleotide position of Mycobacterium gordonae isolates as target on an Mycobacterium tuberculosis rpoB chip compared to a reference ATCC isolate.
  • FIG. 22 A and FIG. 22B (SEQ ID NOS:26-33): Design of a tiled array.
  • FIG. 23 Effect and positional dependence of a single base mismatch on hybrid stability using the MT1 DNA chip. The sequences of the perfect match probe and each A:A single base mismatch probe are shown. The results of five independent experiments are plotted.
  • FIGS. 24A, 24 B and 24 C Detection of base differences in a 2.5 kb region of human mitochondrial DNA between a sample and reference target by comparison of scaled p 0 hybridization intensity patterns.
  • FIGS. 25A and 25B (SEQ ID NOS:34-36): Detection of deletion sequences of human mitochondrial DNA.
  • FIGS. 26A, 26 B and 26 C Hybridization of 16.3 kb of a mitochondrial target to chip with the entire mitochondrial genome.
  • FIG. 27 A and FIG. 27 B (A) Overlay of hybridization intensities of Exon 12 of the MSH2 gene from a patient sample and from a wild type sample. (B) Plot of hybridization intensity differences greater than 0.25 between patient sample and wild type sample as a function of base position.
  • FIG. 28 Plot of hybridization intensity differences greater than 0.25 between patient sample and wild type sample as a function of base position for Exon 13 and Exon 16 of the MLH1 gene.
  • FIG. 29 Plot of hybridization intensity differences greater than 0.25 between patient sample and wild type sample as a function of base position for Exon 12 of the MSH2 gene.
  • FIG. 30 Plot of hybridization intensity differences greater than 0.25 between patient sample and wild type sample as a function of base position for Exon 5 of the p53 gene.
  • FIG. 31 Computer that may be utilized to execute software embodiments of the present invention.
  • FIG. 32 A system block diagram of a typical computer system that may be used to execute software embodiments of the invention.
  • FIG. 33 A high level flowchart of identifying the presence of a polymorphism in a nucleic acid sequence from a patient sample.
  • FIG. 34 A high level flowchart of a method of identifying a species within a genus to which an organism belongs.
  • FIG. 35 A high level flowchart of a method of identifying species within a genus to which organisms belong.
  • FIG. 36 A hierarchical clustering of isolates of Mycobacterium.
  • This invention provides methods, compositions and devices for identifying the group or species of an organism and obtaining functional phenotypic information about the organism based on genotypic analysis of one or more genomic regions of the organism.
  • the method compares a target nucleic acid sequence from the organism coding for a gene (or its complement) to a reference sequence coding for the same gene (or its complement).
  • a reference sequence from any genomic region of the organism can be used.
  • phenotypes When phenotypes are being identified, it will be understood by one of skill in the art that mutations within that region will affect the phenotypic trait which is being characterized.
  • Genotyping by contrast, only requires that a polymorphism, which may or may not code for a mutation, be present.
  • the reference sequence can be from a highly polymorphic region, a region of intermediate polymorphic complexity or in some cases, a highly conserved region. Highly polymorphic regions are typically more informative when doing speciation analysis.
  • a “highly conserved region” of a organism refers to a degree of conservation at the genotypic level of greater than 50%, preferably greater than 75%, and more preferably greater than 90%.
  • a particularly useful reference sequence is the 700 bp rpoB gene from Mycobacterium tuberculosis ( Mt ), since it is well defined.
  • microorganism refers to bacteria, fungi, protozoa or viruses.
  • biological sample refers to a sample obtained from an organism or from components (e.g., cells) of an organism.
  • the sample may be of any biological tissue or fluid. Frequently the sample will be a “clinical sample” which is a sample derived from a patient.
  • samples include, but are not limited to, sputum, blood, blood cells (e.g., white cells), tissue or fine needle biopsy samples, urine, peritoneal fluid, and pleural fluid, or cells therefrom.
  • Biological samples may also include sections of tissues such as frozen sections taken for histological purposes.
  • PCR polymerase chain reaction
  • LCR ligase chain reaction
  • the hybridized nucleic acids are detected by detecting one or more labels attached to the sample nucleic acids.
  • the labels may be incorporated by any of a number of means well known to those of skill in the art. However, in a preferred embodiment, the label is simultaneously incorporated during the amplification step in the preparation of the sample nucleic acids.
  • PCR polymerase chain reaction
  • transcription amplification as described above, using a labeled nucleotide (e.g. fluorescein-labeled UTP and/or CTP) incorporates a label into the transcribed nucleic acids.
  • a label may be added directly to the original nucleic acid sample (e.g., mRNA, polyA mRNA, cDNA, etc.) or to the amplification product after the amplification is completed.
  • Means of attaching labels to nucleic acids are well known to those of skill in the art and include, for example nick translation or end-labeling (e.g. with a labeled RNA) by kinasing of the nucleic acid and subsequent attachment (ligation) of a nucleic acid linker joining the sample nucleic acid to a label (e.g., a fluorophore).
  • Detectable labels suitable for use in the present invention include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means.
  • Useful labels in the present invention include biotin for staining with labeled streptavidin conjugate, magnetic beads (e.g., DynabeadsTM), fluorescent dyes (e.g., fluorescein, texas red, rhodamine, green fluorescent protein, and the like), radiolabels (e.g., 3 H, 125 I, 35 S, 14 C, or 32 P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and calorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads.
  • Patents teaching the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752;
  • oligonucleotide probe array complementary to the reference sequence or subsequence thereof is immobilized on a solid support using one of the display strategies described below.
  • probe arrays derived from the Mycobacterium rpoB gene as an example; however it should be recognized, as described previously, that probe arrays derived from other genes may also be used, depending on the phenotypic trait being monitored, the availability of suitable primers and the like.
  • target nucleic acids derived from Mycobacterium species having rpoB genes of known sequence and known drug resistance mutations are screened against a solid phase probe array derived from sequences complementary to the Mycobacterium tuberculosis rpoB gene (the Mtb rpoB chip).
  • the known sequences are either available from the literature or can be independently established by another method, such as dideoxynucleotide sequencing.
  • the overall hybridization pattern observed with each these species is compared to the overall hybridization pattern observed with Mycobacterium tuberculosis and differences between the two hybridization patterns are derived.
  • the observed patterns will vary as a function of the variation in the sequences of the rpoB genes of the individual species. Subsequences identical to Mt will generate hybridization subpatterns identical to the subpattern observed with Mt for that corresponding subsequence. Subsequences which differ from Mt will generate hybridization subpatterns which differ from the Mt subpattern for that corresponding subsequence.
  • the overall hybridization pattern observed with a particular species allows one to identify regions of the rpoB gene of that species which differ from that of Mt.
  • the presence of a different hybridization pattern in a specified region of the substrate can be correlated with a probability that the target nucleic acid is from a specific species.
  • the differential hybridization pattern in a single region will allow species identification. This can occur when one or more polymorphisms in that region are uniquely associated with a specific species. More frequently however, such an unique one-to-one correspondence is not present. Instead, differential hybridization patterns (i.e., relative to the reference sequence) are observed in multiple regions, none of which will bear an unique correspondence to a particular species. However, each differential hybridization pattern will be associated with a probability of the organism being screened belonging to a particular species (or not) or carrying a particular phenotypic trait (or not).
  • the overall hybridization pattern which is the aggregate of all the differential hybridizations observed at all regions of the substrate, allows one to assign with high confidence, the speciation and/or phenotype of the organism.
  • the differences will be definable, i.e., the different nucleotide responsible for the different hybridization pattern will be known.
  • the difference will not be definable, i.e., all one will know is that a polymorphism is present in that region. However, this is primarily a function of the probe array used on the chip.
  • the sample can be screened against a different probe array to assign the polymorphism present in that region. Since the point mutations which confer antibiotic resistance, for example to rifampacin, for Mt are frequently known, the presence of a change in the hybridization pattern in the region where the point mutation occurs signals the presence of a rifampacin resistant species. It will be apparent that this technique is not limited to identifying drug resistance. Any phenotypic trait whose variation has been mapped to mutations is a particular genomic region can be identified by this method. Representative and nonlimiting examples include the presence of toxin and pathogenic markers.
  • This chip based screening method allows one to build up a data base of hybridization patterns corresponding to different species. Some regions of the hybridization pattern will be shared among subsets of the species because their sequences in regions corresponding to those hybridizations are identical. Other regions of the hybridization pattern will differ between two species because the sequence corresponding to those hybridizations are different. In all cases, the sequences of the rpoB gene of the unknown species are being compared to the corresponding sequence of Mt. Differences in the hybridization pattern of a particular species to the pattern observed with Mt as sample, can be correlated to the presence of a polymorphism at a particular point in the sequence of that species.
  • Some polymorphisms will be definable, i.e., one will know not only that the nucleotide at that position differs from that of Mt, but one will also know the identity of that nucleotide. Some polymorphisms will be unique to the particular species, i.e., species-specific; they will be present in that particular species and not in any other species. Other polymorphisms will be shared, i.e., they will not be unique to a particular species. Certain subsets of species will have the polymorphism and others will not. However, each of these polymorphisms can be assigned to its particular subset of species. Therefore, the presence of a shared polymorphism, despite not indicating with certainty that the sample being screened contains a particular species, increases the probability that one species of that particular subset of species is present.
  • the hybridization pattern of a particular sample can be represented as a “bar code” in which the individual lines of the bar code indicate the presence of a polymorphism relative to Mt.
  • This invention provides a method of screening large numbers of individual species and thus deriving information on the polymorphisms present in those species. Each individual line can be assigned a probability of being associated with different species. In this fashion, a data base can be built up in which increasing numbers of polymorphisms can be associated with the different species.
  • the presence of an unique species-specific polymorphism will allow the immediate identification of a sample as being a particular species. However, even the presence of shared polymorphisms among several species will allow species identification.
  • each species can be assigned a “fingerprint” of shared polymorphisms, i.e., that species and isolates of that species will possess a particular collection of shared polymorphisms.
  • the strengths of this technique is that the rapid screening made possible by the chip-based hybridization allows one to continuously expand the data base of patterns and polymorphisms to ultimately enable the identification of species previously unidentifiable due to lack of sufficient information.
  • the chip-based method of determining hybridization patterns disclosed herein allows one to both build up a data base of polymorphisms associated with a particular species and use that data base to identify the speciation and phenotypic characteristic of an unknown sample from a single hybridization experiment.
  • a second layer of confidence can be added to the initial determination by analyzing whether the differences in hybridization patterns are shared or unique. If the species identified is supposed to have either a shared or unique polymorphism at a particular site and the chip has in fact detected such a polymorphism, then one can be more confident in the initial determination.
  • Both identification and phenotyping can be accomplished based on genotypic determinations of a single region of the mycobacteria genome in place of analysis of two genomic regions (the rpoB and the 16S rRNA genes).
  • Two generic implications can derived from the successful demonstration of the use of high density oligonucleotide arrays for mycobacteria identification and antibiotic drug sensitivity.
  • other genes affecting drug sensitivity can be encoded on the high density oligonucleotide arrays (see Table 1) and hybridization patterns for each of these additional genes can be used to confirm and provide confidence measurements for fingerprints derived from the rpoB gene.
  • the same chip-based strategy could be employed for other eubacteria species which simultaneously could provide genotypic information concerning important clinical phenotypes (e.g., toxin and pathogen marker genes) as well as identification information.
  • Mt rpoB gene has used the Mt rpoB gene as an example. It should be recognized that this method is generally applicable to other microorganisms and reference sequences derived from other genomic regions, such as, for example, the human mitochondrial DNA sequence and the Mt DNA sequence.
  • the length of a reference sequence can vary widely from a full-length genome, to an individual chromosome, episome, gene, component of a gene, such as an exon or regulatory sequences, to a few nucleotides.
  • a reference sequence of between about 2, 5, 10, 20, 50, 100, 500, 1000, 5,000 or 10,000, 20,000 or 100,000 nucleotides is common. Sometimes only particular regions of a sequence are of interest. In such situations, the particular regions can be considered as separate reference sequences or can be considered as components of a single reference sequence, i.e., the microbial genome.
  • a reference sequence can be any naturally occurring, mutant, consensus sequence of nucleotides, RNA or DNA.
  • sequences can be obtained from computer data bases, publications or can be determined or conceived de novo.
  • a reference sequence is selected to show a high degree of sequence identity to envisaged target sequences.
  • more than one reference sequence is selected. Combinations of wild-type and mutant reference sequences are employed in several applications of the tiling strategy.
  • FIG. 31 illustrates an example of a computer system that may be used to execute software embodiments of the present invention.
  • FIG. 31 shows a computer system 100 which includes a monitor 102 , screen 104 , cabinet 106 , keyboard 108 , and mouse 110 .
  • Mouse 110 may have one or more buttons such as mouse buttons 112 .
  • Cabinet 106 houses a CD-ROM drive 114 , a system memory and a hard drive (see FIG. 32) which may be utilized to store and retrieve software programs incorporating code that implements the present invention, data for use with the present invention, and the like.
  • a CD-ROM 116 is shown as an exemplary computer readable storage medium, other computer readable storage media including floppy disks, tape, flash memory, system memory, and hard drives may be utilized.
  • Cabinet 106 also houses familiar computer components such as a central processor, system memory, hard disk, and the like.
  • FIG. 32 shows a system block diagram of computer system 100 that may be used to execute software embodiments of the present invention.
  • computer system 100 includes monitor 102 and keyboard 108 .
  • Computer system 100 further includes subsystems such as a central processor 102 , system memory 120 , I/O controller 122 , display adapter 124 , removable disk 126 (e.g., CD-ROM drive), fixed disk 128 (e.g., hard drive), network interface 130 , and speaker 132 .
  • Other computer systems suitable for use with the present invention may include additional or fewer subsystems.
  • another computer system could include more than one processor 102 (i.e., a multi-processor system) or a cache memory.
  • Arrows such as 134 represent the system bus architecture of computer system 100 . However, these arrows are illustrative of any interconnection scheme serving to link the subsystems. For example, a local bus could be utilized to connect the central processor to the system memory and display adapter.
  • Computer system 100 shown in FIG. 32 is but an example of a computer system suitable for use with the present invention. Other configurations of subsystems suitable for use with the present invention will be readily apparent to one of ordinary skill in the art.
  • oligonucleotide arrays which comprise probes exhibiting complementarity to one or more selected reference sequences whose sequence is known.
  • these arrays are immobilized in a high density array (“DNA on chip”) on a solid surface as described in U.S. Pat. No. 5,143,854 and PCT patent publication Nos. WO 90/15070, WO 92/10092 and WO 95/11995, each of which is incorporated herein by reference.
  • the basic tiling strategy provides an array of immobilized probes for analysis of target sequences showing a high degree of sequence identity to one or more selected reference sequences.
  • the strategy is illustrated for an array that is subdivided into four probe sets, although it will be apparent that satisfactory results are obtained from one probe set (i.e., a probe set complementary to the reference sequence as described earlier).
  • a first probe set comprises a plurality of probes exhibiting perfect complementarity with a selected reference sequence.
  • the perfect complementarity usually exists throughout the length of the probe. However, probes having a segment or segments of perfect complementarity that is/are flanked by leading or trailing sequences lacking complementarity to the reference sequence can also be used.
  • each probe in the first probe set has at least one interrogation position that corresponds to a nucleotide in the reference sequence. That is, the interrogation position is aligned with the corresponding nucleotide in the reference sequence, when the probe and reference sequence are aligned to maximize complementarity between the two.
  • a probe has more than one interrogation position, each corresponds with a respective nucleotide in the reference sequence.
  • the identity of an interrogation position and corresponding nucleotide in a particular probe in the first probe set cannot be determined simply by inspection of the probe in the first set.
  • an interrogation position and corresponding nucleotide is defined by the comparative structures of probes in the first probe set and corresponding probes from additional probe sets.
  • a probe could have an interrogation position at each position in the segment complementary to the reference sequence.
  • interrogation positions provide more accurate data when located away from the ends of a segment of complementarity.
  • a probe having a segment of complementarity of length x does not contain more than x ⁇ 2 interrogation positions.
  • probes are typically 9-21 nucleotides, and usually all of a probe is complementary, a probe typically has 1-19 interrogation positions. Often the probes contain a single interrogation position, at or near the center of probe.
  • FIG. 1 illustrates the basic “tiling” strategy of the invention.
  • the probes from the three additional probe sets are identical to the corresponding probe from the first probe set with one exception.
  • the exception is that at least one (and often only one) interrogation position, which occurs in the same position in each of the four corresponding probes from the four probe sets, is occupied by a different nucleotide in the four probe sets.
  • the corresponding probe from the first probe set has its interrogation position occupied by a T, and the corresponding probes from the additional three probe sets have their respective interrogation positions occupied by A, C, or G, a different nucleotide in each probe.
  • a probe from the first probe set comprises trailing or flanking sequences lacking complementarity to the reference sequences (see FIG. 2 )
  • these sequences need not be present in corresponding probes from the three additional sets.
  • corresponding probes from the three additional sets can contain leading or trailing sequences outside the segment of complementarity that are not present in the corresponding probe from the first probe set.
  • the probes from the additional three probe set are identical (with the exception of interrogation position(s)) to a contiguous subsequence of the full complementary segment of the corresponding probe from the first probe set.
  • the subsequence includes the interrogation position and usually differs from the full-length probe only in the omission of one or both terminal nucleotides from the termini of a segment of complementarity. That is, if a probe from the first probe set has a segment of complementarity of length n, corresponding probes from the other sets will usually include a subsequence of the segment of at least length n ⁇ 2.
  • the subsequence is usually at least 3, 4, 7, 9, 15, 21, or 25 nucleotides long, most typically, in the range of 9-21 nucleotides.
  • the subsequence should be sufficiently long or hybridization conditions such to allow a probe to hybridize detectably more strongly to a variant of the reference sequence mutated at the interrogation position than to the reference sequence.
  • the probes can be oligodeoxyribonucleotides or oligoribonucleotides, or any modified forms of these polymers that are capable of hybridizing with a target nucleic sequence by complementary base-pairing.
  • Complementary base pairing means sequence-specific base pairing which includes e.g., Watson-Crick base pairing as well as other forms of base pairing such as Hoogsteen base pairing.
  • Modified forms include 2′-O-methyl oligoribonucleotides and so-called PNAs, in which oligodeoxyribonucleotides are linked via peptide bonds rather than phophodiester bonds.
  • the probes can be attached by any linkage to a support (e.g., 3′, 5′ or via the base). 3′ attachment is more usual as this orientation is compatible with the preferred chemistry for solid phase synthesis of oligonucleotides.
  • the number of probes in the first probe set depends on the length of the reference sequence, the number of nucleotides of interest in the reference sequence and the number of interrogation positions per probe. In general, each nucleotide of interest in the reference sequence requires the same interrogation position in the four sets of probes.
  • a reference sequence 100 nucleotides, 50 of which are of interest, and probes each having a single interrogation position.
  • the first probe set requires fifty probes, each having one interrogation position corresponding to a nucleotide of interest in the reference sequence.
  • the second, third and fourth probe sets each have a corresponding probe for each probe in the first probe set, and so each also contains a total of fifty probes.
  • the identity of each nucleotide of interest in the reference sequence is determined by comparing the relative hybridization signals at four probes having interrogation positions corresponding to that nucleotide from the four probe sets.
  • the first probe set has interrogation positions selected to correspond to at least a nucleotide (e.g., representing a point mutation) and one immediately adjacent nucleotide.
  • the probes in the first set have interrogation positions corresponding to at least 3, 10, 50, 100, 1000, 20,000, 100,000, 1,000,000, 10,000,000, or more contiguous nucleotides.
  • the probes usually have interrogation positions corresponding to at least 5, 10, 30, 50, 75, 90, 99 or sometimes 100% of the nucleotides in a reference sequence.
  • the probes in the first probe set completely span the reference sequence and overlap with one another relative to the reference sequence.
  • each probe in the first probe set differs from another probe in that set by the omission of a 3′ base complementary to the reference sequence and the acquisition of a 5′ base complementary to the reference sequence.
  • FIG. 3 illustrates an incremental succession of probes in a basic tiling strategy.
  • the number of probes on the chip can be quite large (e.g., 10 5 -10 6 ). However, often only a relatively small proportion (i.e., less than about 50%, 25%, 10%, 5% or 1%) of the total number of probes of a given length are selected to pursue a particular tiling strategy.
  • a complete set of octomer probes comprises 65,536 probes; thus, an array of the invention typically has fewer than 32,768 octomer probes.
  • a complete array of decamer probes comprises 1,048,576 probes; thus, an array of the invention typically has fewer than about 500,000 decamer probes.
  • arrays have a lower limit of 25, 50 or 100 probes and as many probes as 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , etc. probes.
  • the arrays can have other components besides the probes such as linkers attaching the probes to a support.
  • each position in the array is highly informative, whether or not hybridization occurs; (ii) nonspecific hybridization is minimized; (iii) it is straightforward to correlate hybridization differences with sequence differences, particularly with reference to the hybridization pattern of a known standard; and (iv) the ability to address each probe independently during synthesis, using high resolution photolithography, allows the array to be designed and optimized for any sequence. For example the length of any probe can be varied independently of the others.
  • the probes in a set are usually arranged in order of the sequence in a lane across the chip, although this arrangement is not required.
  • the probes can be randomly distributed on the chip.
  • a lane contains a series of overlapping probes, which represent or tile across, the selected reference sequence (see FIG. 3 ).
  • the components of the four sets of probes are usually laid down in four parallel lanes, collectively constituting a row in the horizontal direction and a series of 4-member columns in the vertical direction.
  • Corresponding probes from the four probe sets i.e., complementary to the same subsequence of the reference sequence) occupy a column.
  • Each probe in a lane usually differs from its predecessor in the lane by the omission of a base at one end and the inclusion of additional base at the other end as shown in FIG. 3 .
  • this orderly progression of probes can be interrupted by the inclusion of control probes or omission of probes in certain columns of the array. Such columns serve as controls to orient the chip, or gauge the background, which can include target sequence nonspecifically bound to the chip.
  • the probes sets are usually laid down in lanes such that all probes having an interrogation position occupied by an A nucleotide form an A-lane, all probes having an interrogation position occupied by a C nucleotide form a C-lane, all probes having an interrogation position occupied by a G nucleotide form a G-lane, and all probes having an interrogation position occupied by a T (or U) form a T lane (or a U lane). Note that in this arrangement there is not a unique correspondence between probe sets and lanes. Thus, the probe from the first probe set is laid down in the A-lane, C-lane, A-lane, A-lane and T-lane for the five columns in FIG. 4 .
  • the interrogation position on a column of probes corresponds to the position in the target sequence whose identity is determined from analysis of hybridization to the probes in that column.
  • I 1 -I 5 respectively correspond to N 1 -N 5 in FIG. 4 .
  • the interrogation position can be anywhere in a probe but is usually at or near the central position of the probe to maximize differential hybridization signals between a perfect match and a single-base mismatch. For example, for an 11 mer probe, the central position is the sixth nucleotide.
  • the array of probes is usually laid down in rows and columns as described above, such a physical arrangement of probes on the chip is not essential.
  • the data from the probes can be collected and processed to yield the sequence of a target irrespective of the physical arrangement of the probes on a chip.
  • the hybridization signals from the respective probes can be reasserted into any conceptual array desired for subsequent data reduction whatever the physical arrangement of probes on the chip.
  • a range of lengths of probes can be employed in the chips.
  • a probe may consist exclusively of a complementary segments, or may have one or more complementary segments juxtaposed by flanking, trailing and/or intervening segments. In the latter situation, the total length of complementary segment(s) is more important that the length of the probe.
  • the complementary segment(s) of the first probe sets should be sufficiently long to allow the probe to hybridize detectably more strongly to a reference sequence compared with a variant of the reference including a single base mutation at the nucleotide corresponding to the interrogation position of the probe.
  • the complementary segment(s) in corresponding probes from additional probe sets should be sufficiently long to allow a probe to hybridize detectably more strongly to a variant of the reference sequence having a single nucleotide substitution at the interrogation position relative to the reference sequence.
  • a probe usually has a single complementary segment having a length of at least 3 nucleotides, and more usually at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 30 bases exhibiting perfect complementarity (other than possibly at the interrogation position(s) depending on the probe set) to the reference sequence.
  • all probes are the same length.
  • Other chips employ different groups of probe sets, in which case the probes are of the same size within a group, but differ between different groups. For example, some chips have one group comprising four sets of probes as described above in which all the probes are 11 mers, together with a second group comprising four sets of probes in which all of the probes are 13 mers. Of course, additional groups of probes can be added. Thus, some chips contain, e.g., four groups of probes having sizes of 11 mers, 13 mers, 15 mers and 17 mers. Other chips have different size probes within the same group of four probes. In these chips, the probes in the first set can vary in length independently of each other.
  • Probes in the other sets are usually the same length as the probe occupying the same column from the first set. However, occasionally different lengths of probes can be included at the same column position in the four lanes. The different length probes are included to equalize hybridization signals from probes depending on the hybridization stability of the oligonucleotide probe at the pH, temperature, and ionic conditions of the reaction.
  • the length of a probe can be important in distinguishing between a perfectly matched probe and probes showing a single-base mismatch with the target sequence.
  • the discrimination is usually greater for short probes.
  • Shorter probes are usually also less susceptible to formation of secondary structures.
  • the absolute amount of target sequence bound, and hence the signal is greater for larger probes.
  • the probe length representing the optimum compromise between these competing considerations may vary depending on inter alia the GC content of a particular region of the target DNA sequence, secondary structure, synthesis efficiency and cross-hybridization. In some regions of the target, depending on hybridization conditions, short probes (e.g., 11 mers) may provide information that is inaccessible from longer probes (e.g., 19 mers) and vice versa.
  • Maximum sequence information can be read by including several groups of different sized probes on the chip as noted above. However, for many regions of the target sequence, such a strategy provides redundant information in that the same sequence is read multiple times from the different groups of probes. Equivalent information can be obtained from a single group of different sized probes in which the sizes are selected to maximize readable sequence at particular regions of the target sequence.
  • the additional probe set comprises a probe corresponding to each probe in the first probe set as described above. However, a probe from the additional probe set differs from the corresponding probe in the first probe set in that the nucleotide occupying the interrogation position is deleted in the probe from the additional probe set, as shown in FIG. 5 .
  • the probe from the additional probe set bears an additional nucleotide at one of its termini relative to the corresponding probe from the first probe set (shown in brackets in FIG. 5 ).
  • the probe from the additional probe set will hybridize more strongly than the corresponding probe from the first probe set to a target sequence having a single base deletion at the nucleotide corresponding to the interrogation position. Additional probe sets are provided in which not only the interrogation position, but also an adjacent nucleotide is deleted.
  • one additional probe set has a probe corresponding to each probe in the first probe set as described above.
  • the probe in the additional probe set has an extra T nucleotide inserted adjacent to the interrogation position. See FIG. 5 (the extra T is shown in a square box).
  • the probe has one fewer nucleotide at one of its termini relative to the corresponding probe from the first probe set (shown in brackets).
  • the probe from the additional probe set hybridizes more strongly than the corresponding probe from the first probe set to a target sequence having an A insertion to the left of nucleotide “n” of the reference sequence in FIG. 5 .
  • Similar additional probe sets can be constructed having C, G or A nucleotides inserted adjacent to the interrogation position.
  • the target sequence contains and insertion. For example, if a probe from one of the additional probe sets shows a higher hybridization signal than a corresponding probe from the first probe set, it is deduced that the target sequence contains an insertion adjacent to the corresponding nucleotide (n) in the target sequence.
  • the inserted base in the target is the complement of the inserted base in the probe from the additional probe set showing the highest hybridization signal. If the corresponding probe from the first probe set shows a higher hybridization signal than the corresponding probes from the additional probe sets, then the target sequence does not contain an insertion to the left of corresponding position ((“n” in FIG. 5 )) in the target sequence.
  • a multiple-mutation probe is usually identical to a corresponding probe from the first set as described above, except in the base occupying the interrogation position, and except at one or more additional positions, corresponding to nucleotides in which substitution may occur in the reference sequence.
  • the one or more additional positions in the multiple mutation probe are occupied by nucleotides complementary to the nucleotides occupying corresponding positions in the reference sequence when the possible substitutions have occurred.
  • Another aspect of the invention derives hybridization patterns from a chip with a first probe set comprising a plurality of probes of perfect complementarity to the reference sequence, and optionally, one or more additional probe sets, each additional set comprising probes corresponding to a probe in the first set with an interrogation position for a nucleotide of interest.
  • the probes in the additional probe sets differ from their corresponding probes in the first probe set by having a different nucleotide in the interrogation position.
  • the overall hybridization is derived by plotting the maximum hybridization intensity observed from target hybridization to the group of probes consisting of a probe in the first probe set and its corresponding probes in the additional probe sets versus the nucleotide position of the target being interrogated by this group of probes.
  • the probes are grouped according to groups in which all the probes in a particular group interrogate a common nucleotide position in the sequence being analyzed. These groups are referred to as groups of interrogatory probes.
  • groups of interrogatory probes For example, with reference to FIG. 4, the first column of probes with interrogation position I 1 is interrogating position n 1 , the second column of probes with interrogation position I 2 is interrogating position n 2 and so on.
  • the chip can use a single probe set complementary to the reference sequence; multiple probe sets each of which interrogate a particular position in the target by varying the corresponding nucleotide of interest at that position; or even additional probe sets which are of different lengths to the first and additional probe sets comprising the first set of groups of interrogatory probes.
  • This method, using one set of probes is described in U.S. patent application Ser. No. 08/531,137, filed Oct. 16, 1995, U.S. Pat. No. 5,974,164. A plot obtained from such a method is shown in FIG. 16 . This entire plot is derived from the image gathered from a single hybridization experiment.
  • the shape of this plot will also vary.
  • the following discussion uses a chip with probes complementary to a reference sequence from the Mycobacterium tuberculosis rpoB gene and the plot of maximum hybridization intensity derived from the image observed when the reference sequence (i.e., from an M. tuberculosis sample) is hybridized to the chip is called the baseline or reference plot (or pattern).
  • Target sequences from species of Mycobacterium other than tuberculosis will give plots of different shape.
  • Hybridization experiments with targets of known speciation thus provides a database in which each of these differently shaped plots is correlated with speciation or other genotypic feature, which then in turns allows one to predict the presence of a phenotype. It should be apparent that any gene of interest can be tiled across the chip and that the hybridization pattern derived from the image on the chip from any other sample suspected of containing that gene or polymorphic variant thereof can be used to detect the presence or absence of a particular variant of that gene in the sample.
  • FIG. 16 shows the plot of hybridization intensity as a function of position being interrogated along the reference sequence for the case where the reference sequence is from the Mycobacterium tuberculosis rpoB gene (the Mtb chip described in the Examples) and the target is M. gordonae.
  • FIG. 17 shows similar plots obtained with other Mycobacterium species. It is also noteworthy that species different to M. tuberculosis produce differences in hybridization intensity even from segments of the sequence which are identical to M. tuberculosis. Thus this method allows one to derive information even from subsequences that are identical to M. tuberculosis. As will be apparent, each species produces a characteristic pattern.
  • FIG. 18 shows such an overlay of patterns from different targets versus Mtb as observed on an Mtb chip. As one expects, when the target is M. tuberculosis (bottom panel) the overlay is perfect, whereas when the target is not M. tuberculosis differences are present. Each of these patterns is thus a “fingerprint” for that particular species.
  • FIGS. 19A, 19 B, 19 C and 19 D show such a comparison of an unknown patient sample to fingerprints from four Mycobacterium species showing a match and thus identifying the unknown as being M. gordonae.
  • FIG. 20 shows a similar identification of two other samples (6 and 7, previously incorrectly identified as M. avium by another technique) as M. xenopi and M. intracellulare.
  • sequence used to generate the baseline pattern against which the target pattern is compared need not be that derived from a sample in which the reference sequence was hybridized to the chip. Any other sample that is related to the target sample may be used since the method compares differences between the baseline pattern and the pattern from the unknown target.
  • High density oligonucleotide arrays may be utilized to detect drug resistance conferring mutations using information gathered form gene regions utilized to identify species of isolates within the genus Mycobacterium. For example, the 700 base pairs of the rpoB gene of Mycobacterium may be utilized to detect mutations that confer resistance to rifampin and to detect polymorphisms which allow for the identification of Mycobacterium species.
  • Table 1B indicates the total polymorphic variation observed among the nine non-tuberculosis species compared to M. tuberculosis within the 700 base pairs of rpoB. With any of these non-tuberculosis species there are both species specific (base positions where observed polymorphisms found only with that species) and share (base positions which have polymorphisms found in some of the isolates of that species and some isolates of other Mycobacterium species). Virtually all of these polymorphisms have never been previously described and constitute useful and important markers for the identification of their corresponding species.
  • 16SrRNA sequences are commonly utilized to identify species of Mycobacterium. However, analysis of the hybridization pattern using the rpoB gene indicates that there are some isolates that have been misclassified. For example, two Mycobacterium isolates received from the California Public Health department, 96-1761 and 95-1760, were indicated as M. avium isolates. When the rpoB gene is utilized, it was determined that the most similar match was with M. intracellulare (a close relative of M. avium ).
  • FIG. 34 shows a computer-implemented flowchart of a method of identifying a species within a genus to which an organism belongs.
  • species of nucleic acid sequences from known organisms are input. These nucleic acid sequences will be called “known nucleic acid sequences.”
  • hybridization patterns for the known nucleic acid sequences indicate the hybridization affinity of subsequences of the known nucleic acid sequences to subsequences of a reference nucleic acid sequence.
  • the subsequences of the reference nucleic acid sequence may be portions of nucleic acid probes on a chip.
  • a database of the species and hybridization patterns of the known nucleic acid sequences may be generated. As with other steps, this step is optional but may make identifying species more efficient.
  • the system compares the hybridization pattern of a sample nucleic acid sequence to the hybridization patterns for the known nucleic acid sequences at step 308 , which may be optionally stored in a database.
  • the system determines the species of the organism from which the sample nucleic acid was obtained according to the hybridization pattern of the known nucleic acid sequences that most closely matches the hybridization pattern of the sample nucleic acid at specific locations.
  • an overall pattern matching technique may be utilized, one may also analyze species specific polymorphic locations and/or shared polymorphic locations. Additionally, it may be a combination of hybridization patterns that are utilized to identify the species of the sample nucleic acid sequence.
  • Comparing the hybridization patterns may be done in any number of known techniques.
  • linear regression is utilized across all or selected base positions to normalize the hybridization intensities.
  • a regression coefficient from the linear regression is then utilized to measure the closeness of the hybridization intensities of the hybridization patterns and therefore, the nucleic acid sequences.
  • the system may calculate a probability that the identified species for the sample is correct as indicated at step 310 .
  • FIG. 18 shows plots of hybridization intensities of Mycobacteria species.
  • a DNA assay was designed for Mycobacteria tuberculosis ( Mtb ) as the chip wild-type sequence.
  • Mtb chip This chip will be referred to as the Mtb chip to indicate that the chip was tiled for Mtb .
  • probes that are perfectly complementary to Mtb at sequential base locations. These probes will be referred to as the wild-type probes or probes complementary to the reference sequence.
  • Mtb was hybridized to the Mtb chip and the hybridization intensities of the wild-type probes (here measured as a logarithmic function of the photon counts) vs. the base position is shown in the bottom graph identified as “ Mtb vs. M. tuberculosis.”
  • the graph illustrates an example of a hybridization pattern for Mtb. As indicated by the title of the graph, the graph actually shows the Mtb hybridization intensity pattern vs. itself so that there are actually two hybridization patterns superimposed on each other.
  • the Mtb sequence will be identified as the reference sequence (i.e., is typically a known sequence).
  • each graph shows the hybridization pattern for the reference sequence, Mtb.
  • each species generates a unique hybridization pattern or footprint.
  • a sample sequence which is known to be a Mycobacteria species e.g., from previous base calling algorithms or dideoxy sequencing
  • the hybridization pattern that results may be compared to the hybridization patterns of known sequences to determine the identity of the sample sequence.
  • the Mycobacteria species themselves may have enough similarities that the base calling algorithm is able to identify the sample as a Mycobacteria species.
  • the species may also have enough differences that this method is able to identify the species according to the hybridization pattern.
  • the chip-wild type sequence and the reference sequence were the same sequence, different sequences may be utilized.
  • the hybridization patterns discussed were generated by the hybridization intensities of the wild-type probes. However, hybridization patterns may be generated other ways including utilizing hybridization intensities of the highest intensity probe at each base position. Additionally, the method may be utilized on other species or even unrelated nucleic acid sequences to identify a sample sequence.
  • FIG. 21 shows the patterns observed with different isolates of M. gordonae and their comparison to a single isolate of M. gordonae (ATCC isolate).
  • hybridization intensity vs. nucleotide position patterns and their correlation with patterns of known identity does not require that one identify the base present at particular position of the target or sequence the target. Instead, one determines the maximum hybridization intensity observed from any of the one or more probes which are interrogating for the presence of nucleotide identical to that of the reference sequence at the corresponding position in the target and plots how this changes as a function of base position.
  • the pattern thus obtained is compared to a database of patterns from organisms of known speciation to establish the presence or absence of match. Thus, there is no necessity to “call” or identify any of the bases in the target sequence in order to make an assignment.
  • differences between the target sequence pattern and the baseline reference pattern can be used in the same manner as the presence of differences in nucleotide sequence between target and reference to derive probabilities that the presence of a certain level of difference in hybridization intensity at a particular position indicate a certain species or genotype. All the observed differences from the reference can then be combined to give a composite probability of the sample being of a particular species or genotype.
  • derivation of these patterns of hybridization also allows the use of the “bar code” type of identification method described earlier. As FIG. 16 shows, using patterns derived from hybridization intensity allows one to obtain information from the entire sequence, not just the regions where the sequence of the target differs from that of the reference.
  • One advantage of this method of pattern matching is that provided the same set of probes is used on a chip, one can use different chips at different times and with different concentrations of sample to make the assignment because each different species will produce the same and invariant hybridization pattern. For example, one does not need to derive a control pattern from the reference sequence simultaneous with the analysis of the target to comparing the two patterns (target vs. reference sequence), since the control pattern is invariant and the pattern matching looks at the relative changes in maximum hybridization intensities between succeeding base positions along the sequence. Thus, factors such as amplification conditions and sample concentration which would affect hybridization at all sites equally can be normalized during the analysis.
  • this method of using oligonucleotide arrays with such pattern matching techniques is generally applicable to reference sequences other than the rpoB gene and can be used to detect any differences between a target and reference sequence from any gene.
  • the reference sequence can be from a gene coding for an HIV gene, breast cancer (BRCA-1) or for cystic fibrosis.
  • Software is used to plot the hybridization intensities and compare the pattern so derived to a pattern from the reference or other sequence to establish differences between the target and reference, identity or lack thereof of target to sequence in the database of patterns.
  • Polynucleotide sequence can be represented as an assembly of overlapping oligonucleotides. Therefore, an array consisting of the set of complementary oligonucleotides to a specific sequence can be used to determine the identity of a target sequence, quantitate the amount of the target, or detect differences between the target sequence and a reference. Many different arrays can be designed for these purposes. One such design, termed a tiled array, is depicted schematically in FIG. 22 A.
  • FIG. 22B shows a portion of the fluorescence image of mt 1 fluorescein labelled RNA hybridized to the array. The base sequence can be read by comparing the intensities of the four probes within each column.
  • the column labelled 16,493 consists of the four probes, 3′ TGACAT A GGCTGTAG (SEQ ID NO:1), 3′ TGACAT C GGCTGTAG (SEQ ID NO:2), 3′ TGACAT G GGCTGTAG (SEQ ID NO:3), 3′ TGACAT T GGCTGTAG (SEQ ID NO:4).
  • the probe with the strongest signal is the probe with the A substitution ( A 301, C 57, G 135, T 110 counts), identifying the base at position 16,493 as a U (complementary to the A probe) in the RNA transcript.
  • the rest of the sequence can be read directly from the hybridization intensities.
  • Patterns of signal intensities and their differences resulting from mismatches can be used to advantage in sequence analysis.
  • the loss of hybridization signal from P 0 is a powerful indicator of sequence difference between reference and target. This information is best obtained by hybridizing both the reference and the target sequence simultaneously to the same array.
  • a two-color labelling and detection scheme allowing us to use as an internal standard the hybridization of a reference sample of known sequence (FIG. 24 ).
  • the reference is labelled with phycoerythrin (red) and the unknown target with fluorescein (green). This approach minimizes or eliminates experimental variability during the fragmentation, hybridization, washing, and detection steps.
  • a further advantage is that the sample and reference targets are in competition, enhancing mismatch discrimination.
  • sequences can be identified by directly comparing hybridization amplitude signatures, rather than by comparing analyzed sequences, which may contain embedded errors of interpretation.
  • Hybridization pattern analysis may provide advantages over other methods of detecting sequence variation, or in some cases may be useful in conjunction with them.
  • a second limitation is that if two or more polymorphisms occur within a single probe span, the resulting destabilization tends to reduce the accuracy of sequence interpretation, although the existence of a change can easily be inferred from the loss of signal (FIG. 24 ).
  • the derived sequences were separated into two categories: one that could be read directly with high accuracy, and a second that required further analysis for definitive sequence assignment.
  • the first category was defined as having a derived sequence with no more than a single mismatch with each p 0 probe, and agreement between the derived sequence and p 0 footprint patterns.
  • the p 0 intensity footprints were detected in the following way: the reference and sample intensities were normalized, and R, the average of log 10 (p 0 reference/p 0 sample) over a window of 5 positions, centered at the base of interest, calculated for each position in the sequence.
  • R the average of log 10 (p 0 reference/p 0 sample) over a window of 5 positions, centered at the base of interest, calculated for each position in the sequence.
  • R the average of log 10 (p 0 reference/p 0 sample) over a window of 5 positions, centered at the base of interest, calculated for each position in the sequence.
  • R the average of log 10 (p 0 reference/p 0 sample) over a window of 5 positions, centered at the base of interest, calculated for each position in the sequence.
  • Footprints were detected as regions having at least 5 contiguous positions with a reference or sample intensity of at least 50 counts above background, and an R value in the top 10th percentile for the experiment.
  • the mean R value was 1.01, with a standard deviation of 0.57.
  • the mean R value was ⁇ 0.05, with a standard deviation of 0.25.
  • the second category had a derived sequence with multiple mismatches and/or disagreement between derived sequence and p 0 patterns. For example, the region of iefOO7 shown in FIG. 24A would fall into the first category, if the sequence were called correctly. A false positive basecall would lack a footprint or would result in the prediction of multiple mismatched probes, and be flagged in either case. False negatives are detected by the presence of a footprint despite a “wild-type” basecall.
  • FIG. 25 A An example of a false negative basecall resulting from the use of a limited probe set is shown in FIG. 25 A.
  • the array is designed to read (CA) 5 , but the MT2 target hybridizes sufficiently well to be read as “wild type”.
  • a footprint is detected, and therefore, the region is flagged for further analysis, some differences in hybridization patterns are secondary effects of a change elsewhere in the target.
  • FIG. 25 A An example that is likely due to a sequence-specific difference in target secondary structure is shown in FIG. 25 A. This example shows that the interpretation of difference patterns is not always straightforward. In general, however, the difference patterns provide a substantial amount of additional information that aids sequence analysis.
  • each 2.5 kb PCR amplicon was sequenced on both strands by primer-directed fluorescent chain-terminator cycle sequencing using an ABI373A DNA sequencer, and assembled and manually edited using Sequencher 3.0. Hybridization analysis was also performed on both strands.
  • the analysis presented here assumes that the sequence amplified from genomic DNA is essentially clonal, or at least contains one predominant species, and that its determination by gel-based methods is correct. PCR amplification errors might contribute a maximum of—0.5% sequence difference, essentially randomly distributed, based on an estimation of—10 5 fold amplification and known error rates of Taq polymerase. This would not be expected to affect significantly the results of gel based sequencing or hybridization analysis, particularly when analyzing differences from a reference hybridization pattern.
  • Basecalling was performed using a Bayesian classification algorithm based on variable kernel density estimation.
  • the likelihood of each basecall associated with a set of hybridization intensity values was computed by comparing an unknown set of probes to a set of example cases for which the correct basecall was known. The resulting four likelihoods were then normalized so that they summed to 1. Data from both strands were combined by averaging the values. If the most likely basecall had an average normalized likelihood of greater than 0.6, it was called, otherwise the base was called an ambiguity.
  • the example set was derived from 2 different samples, ib013 and ief005, which have a total of 35 substitutions relative to MT1 of which 19 are shared with the 12 samples analyzed and 16 are not. Base calling performance was not sensitive to the choice of samples.
  • the hybridization sequence analysis was fully automated, with no user editing. In contrast, conventional sequencing required contig assembly followed by editing, in which >1% of basecalls were manually corrected.
  • arrays have a lower limit of 25, 50 or 100 probes and an upper limit of 1,000,000, 100,000, 10,000 or 1,000 probes. A range of lengths of probes may be employed.
  • each of the high density oligonucleotide arrays contain 10,000-20,000 oligonucleotide probes (length 10-20 mers) which are used to determine the sequence of a target nucleic acid (RNA or DNA).
  • the density of the different oligonucleotides is greater than about 60 different oligonucleotides per 1 cm 2 .
  • the determination of a target sequence is accomplished by carrying out a single hybridization reaction involving all of the probes on the surface of the chip. The following is a brief overview describing the synthesis, array design, sample preparation/fluorescent labeling and base calling features of the DNA chips used in this invention.
  • DNA chips use light directed synthesis to build oligonucleotide probes on the surface of the chip (Fodor, et al., Science, 251:767-73 (1991)).
  • This light-directed synthesis combines semiconductor based photolithography and solid phase chemical synthesis.
  • FIG. 6 the process begins when linkers modified with photochemically removable protecting groups (C) are attached to a solid substrate, the chip surface.
  • Linkers and phosphoramidites with photolabile protecting groups have been synthesized and are described by Pease, et al., PNAS, 91:11241-11245 (1994).
  • Light is directed through a photolithographic mask to specific areas of the synthesis surface, activating those areas for subsequent chemical coupling.
  • the masks of cycle 2 are perpendicular to those of cycle 1 , and each synthesis round generates four new dinucleotides until all 16 possible dinucleotides are made (FIG. 7 ).
  • the masks of cycle 3 further subdivide the synthesis regions so that each coupling round generates 16 trimers.
  • the subdivision of the substrate is continued through cycle 4 to form all possible 256 tetramers (complete combinatorial array).
  • the successful demonstration of light-directed complete combinatorial array has recently been described (Pease, et al., PNAS, 91:11241-11245 (1994)). It is important to note that any subset of a complete array can be synthesized by modifying the mask patterns used in each cycle and round of synthesis.
  • the complete combinatorial arrays can be used for applications in which de novo sequencing is sought (Fodor, et al., 1993), while a subset of combinatorial arrays can be used for resequencing applications such as will be employed in this application.
  • the target nucleic acid mycobacterium genomic DNA
  • PCR polymerase chain reaction
  • PCR amplified copies of the target nucleic acid are converted from double stranded (ds) DNA into fluorescently-labeled single stranded (ss) RNA during an in vitro transcription (IVT) reaction.
  • ds double stranded
  • ss single stranded
  • IVT in vitro transcription
  • the fluorescein-labeled target gene specific RNA transcripts are fragmented into oligomer length targets under elevated temperature and 30 mM Mg ++ .
  • the precise protocols, primers and conditions for sample extraction, amplification, chip hybridization and analysis are described in the Examples. Of course other labelling strategies may be utilized.
  • a target gene sequence can be represented on a chip in a series of overlapping oligonucleotide probes arrayed in a tiling strategy (FIG. 9 ).
  • each base in the target is interrogated by using a collection of 4 oligonucleotide probes which are identical except for the base located at or near the center of the probe.
  • Each of the four probes contains dA, dT, dC or dG at this interrogation position.
  • the one which is the exact complement will produce the most stable hybrid and thus the strongest fluorescent signal after post-hybridization washing the DNA chip.
  • next nucleotide in the target sequence can be interrogated with four identical length probes which are the same as the first four except they are offset one nucleotide downstream.
  • the central base of these probes also have all four possible bases.
  • all of the bases of a target sequence can be interrogated using overlapping probes arranged in a tiling strategy.
  • the determination of which of the four possible probes is the complement to target is made by taking the ratio of highest to next highest hybridization signal. If this ratio is greater than 1.2, then a specific determination of the interrogated base can be made. If the highest hybridization signal does not meet this criteria then an ambiguous determination is made based on the IUPAC sequence codes.
  • the sensitivity of DNA chip probes to detect single base mismatches is illustrated using a 16 step combinatorial synthesis.
  • the photolabile MenPoc-dA and MenPoc-dT were the only nucleotides used during the synthesis of the probes on the chip.
  • the lithographic masks were chosen such that each of 256 octanucleotides were synthesized in four independent locations on a 1.28 ⁇ 1.28 cm chip surface. This yielded an array of 1024 octanucleotides each occupying a 400 ⁇ 400 ⁇ m synthesis region.
  • the glass substrate was mounted in a thermostatically regulated hybridization cell.
  • the target employed for this experiment was an oligonucleotide 5′-AAAAAAAA-fluorescein-3′ present in a 1 nM concentration.
  • the chip was scanned using an epi-fluorescent confocal reader.
  • the fluorescent intensities of each of the hybridization events were plotted against the position of the mismatches of the probes on the surface of the chip (FIG. 10 ).
  • the position zero mismatch (with the perfect complement 3′-TTTTTTTT-5′) is the brightest hybridization on the array with the background signal of this array at approximately 220 counts.
  • Mismatch position 1 (at the 3′ end of the probe) (3′-ATTTTTTTT-5′) is the next highest hybridization.
  • the resulting “U” shaped curve indicates the relative stability of the mismatches at each position of the probe/target complex.
  • the mismatches at positions 3, 4, 5 and 6 are very destabilizing and the intensities of these hybridizations are approximately 3 fold lower than the perfect match hybridization.
  • the mismatch at position 1 (the point where the octanucleotide is tethered to the chip substrate) is less destabilizing than the corresponding mismatch at position 8 (5′ free end).
  • the uniformity of the array synthesis and the target hybridization is reflected in the low variance of the intensities of the four duplicate synthesis sites.
  • Hybridization patterns derived from the oligonucleotide probe arrays can be correlated with the drug resistance phenotype and speciation of the organism using mathematical pattern recognition algorithms, such as tree-structured classification techniques. It is important to note that as the total number of analyzed isolates for each species is increased, it is unlikely that a single and unique core fingerprint will define a mycobacterium species. Rather, it is expected that any particular isolate of a Mycobacterium species will have a subset of all possible fingerprints. Identification of the Mycobacterium species based on a fingerprint pattern will require a classification analysis built upon a collected database consisting of species specific and shared SNPs and fingerprints.
  • the goal of identifying an unknown rpoB hybridization pattern as coming from one of the Mycobacterium species in the data base is a general classification problem. Measurements (sequence and fingerprint data) are made on a collection of samples. Based on these measurements a systematic way is developed to predict the class (species) of each member of the collection. The signal produced by the target at each hybridization site is compared to the signal produced by Mt rpoB. Based on this comparison one determines whether or not there is a difference in genotype at the interrogated at that site in the target relative to Mt rpoB.
  • Classifier construction is based on past experience. In systematic classifier construction, past experience is summarized by a learning sample (a.k.a. design or training sample). This consists of the measurement data on N cases observed in the past together with their actual classification. It is intended that the database collected in Phase I will serve as the initial training sample.
  • a learning sample a.k.a. design or training sample.
  • categorical variables There are two general types of variables that can appear in the measurement data, ordered or numerical variables and categorical variables.
  • a variable is called ordered or numerical if its measured values are real numbers.
  • a variable is categorical if it takes values in a finite set not having any natural ordering. In our case, each nucleotide position in the sequence is a variable. So all measurement variables are categorical.
  • the set of measurement variable for a given case is called the measurement vector.
  • the measurement space is defined as the set of all possible measurement vectors.
  • the four most commonly used classification procedures are discriminant analysis, kernel density estimation, and kth nearest neighbor, and tree-structured classification. Discriminant analysis assumes that all the measurement vectors are distributed multivariate normal, and thus is not set up to handle categorical variables (See Gnanadesikan, R. Methods for statistical data analysis of multivariate observations (Wiley, New York (1977)). Even though kernel density estimation and kth nearest neighbor methods make minimal assumptions about the form of the underlying distribution of the measurement vectors, there are still serious limitations common to both methods. They require a definition of a distance measure (metric) among the measurement vectors; performance of these classifiers is sensitive to the choice of the metric. There is no natural or simple way to handle categorical variables.
  • Tree-structured classification is a recursive and iterative procedure. It proceeds by repeated splits of subsets of the measurement space into two descendant subsets or nodes, beginning with the full measurement space.
  • the fundamental approach is to select each split of a node so that the data in each of the descendant nodes are “purer” than the data in the parent node.
  • a node impurity measure is defined such that it is largest when all classes are equally mixed together in that node, and smallest when the node contains only one class.
  • the sequence of splits is determined such that at each candidate node all possible splits are examined and the split that produces the largest decrease in the impurity is selected.
  • the terminal nodes form a partition of the measurement space.
  • Each terminal node is designated by a class assignment based on the observed proportions of the classes in that partition. (Usually, the assignment is the class with the highest proportion.) There may be two or more terminal nodes with the same class assignment.
  • the partition corresponding to that class is obtained by putting together all terminal nodes corresponding to the same class.
  • the tree classifier predicts a class for a given measurement vector in the following way: From the definition of the first split, it is determined whether the measurement vector goes to the right or to the left. This is repeated until the case moves into a terminal node. The predicted class is then given by the class assignment of that terminal node.
  • the optimal size of a classification tree is determined in the following manner: continue the splitting until all terminal nodes are very small, resulting in a large tree. This large tree is then selectively pruned upward, and thus producing a decreasing sequence of subtrees. Finally, use cross-validation or test-sample estimates to choose from the sequence of subtrees that subtree having the lowest estimated misclassification rate.
  • the tree-structured classification methodology is covered in detail in Breiman et. al. Classification and Regression Trees, (Wadsworth International Group, Belmont, Calif. (1984)).
  • the tree-structured approach is a powerful and flexible classification tool. It can handle both numerical and categorical variables in a simple and natural way.
  • the final classification has a simple form that can be efficiently used to classify new data. It does automatic stepwise variable selection and complexity reduction. It provides both the classification and the estimate of the misclassification probability for a new case.
  • the output of the tree procedure gives easily understood and interpreted information regarding the predictive structure of the data.
  • FIG. 11 displays a hypothetical six-class tree (numbers under boxes).
  • the boxes represent nodes.
  • Node t1 contains the whole measurement space and is called the root node.
  • Nodes t2 and t3 are disjoint with t1 being the union of t2 and t3.
  • t4 and t5 are disjoint and t2 is the union of t4 and t5.
  • Those nodes that are not split, in this case, t6, t8, t10, t11, t12, t14, t15, t16, and t17 are called terminal nodes.
  • the numbers beneath the terminal nodes are the class assignments or class labels for this particular classifier.
  • the splits are formed by setting conditions on the coordinates of x.
  • This classifier predicts a class for the measurement vector x in this way: From the definition of the first split, it is determined whether x goes into t2 or t3. For example, if the above definition for Split 1 is used, x goes into t2 if the 10th nucleotide in that sequence is either A or C, otherwise, x goes into t3. If x goes into t2, then from the definition of Split 2, it is determined whether x goes into t4 or t5, and so on. When x finally moves into a terminal node, its predicted class is given by the class label attached to that terminal node.
  • a high density oligonucleotide array ( Mtb rpoB chip) has been synthesized and tested in preliminary experiments.
  • the chip has been synthesized using 2 lengths of oligonucleotides (18 and 20 mers) with the interrogation position located at bases 9 and 10 (sense and antisense probes) and 10 and 11 (sense and antisense probes).
  • the Mtb rpoB chip was used initially to genotype 15 M. tuberculosis clinical isolates which were previously determined to be RIF sensitive.
  • Oligonucleotide primer sequences were as follows.
  • Chromosomal DNA from M. tuberculosis was isolated by suspending one colony in 100 ⁇ l of ddH 2 O, boiling for 10 minutes and briefly centrifuging to separate the DNA solution from cellular debris. The chromosome DNA was then diluted 1:10 in ddH 2 O. A 705 bp rpoB fragment was amplified in a 100 ⁇ l reaction volume containing each dNTP at 200 ⁇ M, each primer at 0.2 ⁇ M, 2.5 U of Taq-polymerase (BM, Indianapolis, Ind.), 10 mM Tris (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 .
  • the amplification was carried out in a model 9600 thermocycler (Perkin Elmer Cetus).
  • rpoB-4 CTC GGA ATT AAC CCT CAC TAA AGG GAC CCA GGA CGT GGA GGC GAT CAC ACC GCA
  • rpoB-7 TAA TAC GAC TCA CTA TAG GGA GAC GTC GCC GCG TCG ATC GCC GCG C
  • T3 and T7 sequences 5 min 95° C., 35 cycles of 1 min 95° C., 30 sec 68° C. and 2 min at 72°, followed by 10 min of 72° were used.
  • the PCR amplicon was then purified using Amicon Microcon 100 columns.
  • In vitro transcription of approximately 50 ng amplicon was performed in a reaction volume of 20 ⁇ l, containing 1.25 mM rNTPs, 10 mM DTT, 125 ⁇ m F-CTP, 20 U RNase inhibitor, 40 mM Tris-HCl (pH7.5), 6 mM MgCl 2 , 2 mM spermidine, 10 mM NaCl, 20 U T3/T7 RNA-polymerase for 90 min at 37° C.
  • the RNA was then purified with Amicon Microcon 100 columns and quantitated using a spectrophotometer.
  • Fragmentation was carried out in 30 mM MgCl 2 at 95° C. for 30 min.
  • a 20 nM RNA solution in 6 ⁇ SSPE, 20% formamide, 0.005% Triton, 0.5 nM control oligo was heated to 68° C. for 10 min, then placed on ice for 5 min and hybridized to the Mtb rpoB chip for 30 min at 22° C. in the Affymetrix Fluidics Station.
  • the post-hybridization wash was performed with 1 ⁇ SSPE, 20% formamide, 0.005% Trition ⁇ 100 in the Affymetrix Fluidics Station (Affymetrix, Santa Clara, Calif.), using 12 wash cycles with 2 fills and drains per cycle, followed by a wash with 6 ⁇ SSPE, 0.005% Triton, 2 cycles with 2 fills and drains per cycle.
  • the chip was then scanned on a Molecular Dynamics scanner (Molecular Dynamics, Santa Clara, Calif.) at 22° C. with a resolution of 11.25 pixels/ ⁇ m.
  • tuberculosis isolates have no mutation in the 81 bp region of rpoB, this isolate may be resistant because of a mutation in the portion of rpob not analyzed by the chip or because of a mutation in some other gene which controls uptake, metabolism or drug binding.
  • the sequences derived using the chip for all 8 isolates were confirmed using dideoxynucleotide sequencing.
  • An Additional 4 RIF resistant isolates were also screened. Mutations only within the 81 bp region were detected for each of these isolates by the Mtb rpoB chip and confirmed by dideoxynucleotide sequencing.
  • a total of 25 M. tuberculosis isolates were analyzed. Seven of these were rifampicin resistant and had the mutations shown in Table 2. Other than the mutations shown in Table 2, there were no polymorphisms in any of the 25 isolates.
  • Amino acid and nucleotide number system employs sequencing derived by Miller, et. al., (1993). 2. Resistance was determined using relative/proportion method of Small et al., “Tuberculosis: Pathogenesis, Protection, and Control” pp. 569-586 (1994) (Am. Soc. Microbiol., ed. B. R. Bloom)
  • the first steps in assembling a database capable of identifying mycobacteria species were taken with the analysis of 7 clinically important Mycobacteria species: M. gordonae, M. chelonae, M. kansasii, M, scrofulaceum, M. avium, M. intracellulare and M. xenopi.
  • M. gordonae M. chelonae
  • M. kansasii M, scrofulaceum
  • M. avium M. intracellulare and M. xenopi.
  • the 700 bp region of the rpoB gene from one isolate from each of these species was sequenced using dideoxynucleotide methodology. Nucleotide (60-71) and amino acid (5-8) differences were compared to M.
  • SNP single nucleotide polymorphisms
  • species specific unique
  • shared shared.
  • the SNPs which were shared with at least 3 other non-tuberculosis mycobacteria are numerous and scattered throughout the 700 bps analyzed.
  • FIG. 12 illustrates the location of these shared SNPs.
  • the species specific SNPs are, however, considerably fewer.
  • FIG. 13 depicts the location and nature of the SNPs for each of the 7 species analyzed based on one isolate for each species.
  • a full fingerprint pattern is composed of identified (unique or shared polymorphisms) and unidentified (clustered polymorphisms leading to no base calling determination) differences.
  • An average of 27.7% of the 700 bps interrogated are viewed as different than if a M. tuberculosis target were hybridized to the chip (Table 4).
  • the chip sees three bases as different from Mtb . This is due to, in addition, each of the two bases flanking the base identified by ABI as polymorphic also being viewed as different by the chip, because of destablization of hybridization at these sites.
  • FIG. 15 presents the images of the sense strand hybridization. Below each chip image is the hybridization fingerprint computed after analysis of both strands. The shared differences among the 11 (10 new and 1 original) isolates analyzed are shown below (Table 5). From this analysis a core (consensus) fingerprint pattern for M. gordonae was derived (FIG. 15 ).
  • a similar core fingerprint has been derived for eight other Mycobacterium species, thus allowing identification of those species. It will be apparent that the techniques described above can be used to assemble a database of species-specific and shared polymorphisms which can be used to derive fingerprints for other species.
  • Fluorescein labelled target RNA was synthesized and fragmented, and the transcription mixture diluted 20-fold in 6 ⁇ SSPE, 0.05% Triton X-100, to give approximately 1 to 10 nMRNA (estimated prior to fragmentation). Hybridization was carried out for 30 min at RT. The chip was washed for a total of 5 to 10 minutes in several changes of 6 ⁇ SSPE, 0.005% Triton X-100, and scanned.
  • FIG. 22A shows the design of the tiled array on the MTI chip.
  • Each position in the target sequence (upper case) is interrogated by a set of 4 probes on the chip (lower case), identical except at a single position, termed the interrogation base, which is either A, C, G, or T.
  • the target will be perfectly complementary to one of the 4 probes, but mismatched with the others. As illustrated in FIG. 10, the perfect complement gives a more intense hybridization signal than do the mismatches.
  • a nucleic acid target of length N can be scanned for mutations with a tiled array containing 4N probes.
  • B Hybridization to a tiled array and detection of a point mutation.
  • the array shown was designed to the MT1 target sequence. When hybridized to MTI (upper panel), one probe in each set of 4 in a column is perfectly matched to the target, while the other three contain a single base mismatch.
  • the interrogation base used in each row of probes is indicated on the left of the image.
  • the target sequence can be read 5′ to 3′ from left to right as the complement of the interrogation base with the brightest signal.
  • Hybridization to MT2 (lower panel), which differs from MT1 in this region by a T ⁇ >C transition, affects the probe sets differently.
  • the G probe is now a perfect match to MT2, with the other three probes having single base mismatches. ( A *, C *, G *, T * counts).
  • the probes have either single or double base mismatches, since the MT2 substitution now occurs away from the interrogation position. The location of the mismatch is illustrated in the probe schematic by red circles.
  • each 2.5 kb target sequence was PCR amplified directly from genomic DNA using the primer pair L14675-T3 (5′aattaaccctcactaaagggATTCTCGCACGGACTACAAC) (SEQ ID NO:7) and H667-T7, transcribed to give RNA targets labelled with fluorescein or biotin, pooled and fragmented as described.
  • the MT1 reference target was biotin labelled and the sample target fluorescein labelled.
  • Targets were diluted 180 fold from the transcription reaction to a final concentration of—100 to 1000 pM in 3 M TMAC1, 10 MM Tris.Cl pH 8.0, 1 mM EDTA, 0.005% Triton X-100, and 0.2 nM of a control oligonucleotide, 51 fluorescein-CTGAACGGTAGCATCTTGAC (SEQ ID NO:8).
  • a control oligonucleotide 51 fluorescein-CTGAACGGTAGCATCTTGAC (SEQ ID NO:8).
  • Hybridization was carried out in packaged chips. Samples were denatured at 95° C. for 5 min. chilled on ice for 5 min.
  • Two scans were collected, one using a 530 DF 25 nm bandpass filter, and the second using a 560 nm longpass filter. Signals were deconvoluted to remove spectral overlap and average counts per cell determined.
  • the sample probe intensities were scaled to the reference intensities as follows: a histogram of the base-10 logarithm of the intensity ratios for each pair of probes was constructed. The histogram had a mesh size of 0.01, and was smoothed by replacing the value at each point with the average number of counts over a five-point window centered at that point. The highest value in the histogram was located, and the resulting intensity ratio was taken to be the most probable calibration coefficient.
  • FIG. 24 The data are shown in FIG. 24 for L strand targets hybridized to H strand probes, from a portion of hypervariable region I in the mitochondrial control region. Numbering is conventional. In each plot, the reference target intensities are shown in red and the sample in blue. The reference, MT1, is a perfect match to the p 0 probes.
  • FIG. 24 A Comparison of iefOO7 to MT1. There is a single base difference between the two target sequences, located at position 16,223 (MT1 C: iefOO7 T).
  • FIG. 24 B Comparison of haOO1 to MT1.
  • the haOO1 target has 4 polymorphisms relative to MT1.
  • the p 0 intensity pattern clearly shows two regions of difference between the targets. Furthermore, it can easily be seen that each region contains >2 differences, because in both cases the footprints are longer than 20 positions, and therefore are too extensive to be explained by a single base difference.
  • the effect of competition can be seen by comparing the MT1 intensities in the iefOO7 and haOO1 experiments: the relative intensities of MT1 are greater in panel B where haOO1 contains po mismatches but iefOO7 does not.
  • FIG. 24 C The haOO4 sample has multiple differences to MT1, resulting in a complex pattern extending over most of the region shown. Thus, differences are clearly detected, even though basecalling might be compromised using only the 4N tiling array. Even when patterns are highly complex, samples can be compared and matched. For example, if the haOO4 sample is compared to haOO4 as a reference in the same experiment, the p 0 pattern indicates a match, even though the effect of multiple mismatches might compromise direct sequence reading (not shown).
  • FIG. 25A shows that although the 4N array was not designed to detect length polymorphisms, this common 2 bp length polymorphism located at 514-523 in the Mt DNA was easily detected by the presence of a po intensity footprint.
  • FIG. 25B shows target-specific effects on hybridization.
  • a 2 bp difference between the MT1 reference (GG) and the haOO2 target (AA) is associated with a complex footprint pattern: the po signals of the mismatched haOO2 hybrids are up to 10-fold higher than those of the perfectly attached mt1 hybrids in a region extending leftwards from position 16,381. Both samples were hybridized simultaneously to the same array.
  • FIG. 26A shows an image of the array, actual size hybridized to L strand target sample.
  • the 1.28 ⁇ 1.28 cm, p 20,9 tiled array contains a total of 134,688 probes, each synthesized in a 35 ⁇ 35 micron cell. The number of probes is sufficient to represent the 16.6 kb genome twice over.
  • the array has the capacity for sense and antisense coding.
  • the 16,569 bp map of the genome is shown and the H strand origin of replication (OH)′ located in the control region, is indicated.
  • FIG. 26 B A portion of the hybridization pattern is shown, magnified. The scale is indicated by the bar on the left hand side. Most of the array can be read directly.
  • FIG. 26 C The ability of the array to detect and read single base differences in a 16.3 kb sample is illustrated.
  • Two different target sequences were hybridized in parallel to different chips. The hybridization patterns are compared for four different positions in the sequence. The top panel of each pair shows the hybridization of a the MT3 target, which matches the chip po sequence at these positions. The lower panel shows the pattern generated by a sample from a patient with Leber's Hereditary Optic Neuropathy (LHON). Three pathogenic mutations are implicated, LHON3460, LHON4216, and LHON13708. All three are clearly detected. For comparison, the third panel in the set shows a region that is identical in both samples, around position 11,778.
  • LHON Hereditary Optic Neuropathy
  • the pattern matching techniques described above also provide a method of determining whether the nucleic acid sequence of a biological sample is homozygous or heterozygous for a particular allele, i.e., to identify the presence of a polymorphism in the nucleic acid sequence at a particular position.
  • polymorphisms can be identified in both coding and noncoding sections of the sample nucleic acid, i.e., in exons or introns. This is of value, for example, in identifying whether a genetically linked disease is present.
  • any genetically related condition i.e., other than those thought as “diseases” can be identified by such a method.
  • FIG. 33 shows a computer-implemented flowchart of a method of identifying the presence of a polymorphism in a nucleic acid sequence from a patient sample.
  • the flowcharts described herein are for illustration purposes and not limitation.
  • FIG. 33 describes analyzing one base position at a time to detect polymorphisms.
  • each step may also be performed for the entire nucleic acid sequences and/or some steps may be combined.
  • the system selects a base position in the nucleic acid sequence from the patient sample.
  • the system determines the difference between the hybridization intensities of the nucleic acid sequence from the patient sample and a corresponding nucleic acid sequence from a wild type sample to an array of reference nucleic acid probes at step 202 .
  • the reference nucleic acid probes may perfectly complementary to the wild type sample, this is not required.
  • the system derives or calculates a ratio of the difference determined at step 202 to the hybridization intensity of the nucleic acid sequence from the wild type sample.
  • the ratio is derived at step 204 and it indicates how close the hybridization intensities for the nucleic acid sequences from the patient wild type samples are to being the same.
  • An assigned value is utilized to determine if the ratio indicates that there is a polymorphism at the base position.
  • the assigned value may be user specified and at step 206 , the system compares the ratio to the assigned value. If the ratio is greater than the assigned value, the system identifies the presence of a polymorphism at the base position of the nucleic acid sequence from the patient sample. At step 210 , the system determines if there is a next base position to analyze.
  • FIGS. 27-30 show such comparisons of patient DNA samples from heterozygous MSH2, MLH1, MSH2 and p53 genes and their corresponding wild type genes.
  • the screening can be against any reference sequence immobilized on the chip, though as described earlier it will be advantageous to use a chip in which the reference sequence is complementary to the wild type sequence.
  • the hybridization intensities corresponding to each base position is determined for each sample as described earlier.
  • This ratio can vary between one and zero, being zero if the wild type and patient sequences are identical in this region (since hybridization will be identical for both samples) and approaching one if there is a complete mismatch, i.e., no hybridization at all between patient sample and the reference sequence in that region. If this ratio is greater than an assigned value, it indicates a polymorphism at that particular base position. Typically, this assigned value is set at about 0.5, preferably 0.6. Positions at which such polymorphisms are present can be identified by plotting this ratio versus the corresponding base position for all positions where the ratio is greater than about 0.25. If the ratio is less than 0.25, this is considered to be statistical noise. Typically such plots will show a spike, with a maximum ratio of about 0.5, centered approximately around the site of the polymorphism. The plots are made with variables derived as follows:
  • the technique has been refined further to provide a higher level of accuracy by determining hybridization intensities from both the sense and antisense strands of the DNA sample and requiring that the spike occur in both strands at the same respective complementary positions.
  • the probes on the chip are typically 10-20 mers and therefore create a “footprint” as one tiles through the position where the polymorphism is present, i.e., there will be a difference between the hybridization intensities of the patient sequence and the wild type sequence in this region.
  • an even higher level of confidence that a polymorphism occurs at a particular base position is obtained by requiring that the hybridization intensity ratio derived above be greater than the assigned value, 0.5 in this example, for at least two adjacent base positions, preferably three adjacent positions.
  • T1 has a substitution at position 11, T2 at position 9, and T3 at positions 9 and 11.
  • S the position of the substitution is noted by S.
  • Each of these targets is hybridized with a DNA chip containing a tiled arrays of probes.
  • a p 7 4 chip is described herein.
  • the superscript 7 indicates that the chip contains a tiled array of 7-mer probes that are perfectly or partially complementary to the reference target.
  • the subscript 4 denotes the interrogation position, such that the nucleotide at position 4 of each 7-mer is varied (A, T, G, or C in four different synthesis cells).
  • the number of target-probe mismatches is given in Table 7 below.
  • the top row gives the number of mismatches for the best-match case (i.e., for the most complementary probe of each set of four) and the second row gives the number of mistmatches for the other three probes in the set.
  • the number of mismatches in this case is the same as that given by the best-match case above except for an additional mismatch at each substitution position (See Table 9).
  • P 7 has one more mismatch at positions 8 and 11, where T3 has substitutions, than does P 7 4 .
  • the effects of multiple substitutions are additive.
  • the effect of the substitution at a is to give 1 mismatch from a ⁇ 1 to a ⁇ 9, and from a+1 to a+6.
  • the substitution at b will give 1 mismatch from b ⁇ 1 to b ⁇ 9, and from b+1 to b+6. If a and b are at positions 100 and 108, their effect is the sum, as shown in Table 10.
  • the first step is to hybridize a P n j chip with the reference target, and another P n j chip with the unknown target.
  • a single P n j chip could be hybridized with a mixture of differently labeled reference and unknown targets (e.g., a red-fluorescent reference target and a green-fluorescent unknown target).
  • a pair of chips, or a pair of suitably labeled targets one can readily identify probes that contain mismatches and distinguish between 0, 1, 2 and a larger number of mismatches.
  • a substitution at location a is identified by the presence of a 1-mismatch zone that is n-residues long except for a 0-mismatch cell at residue a.
  • the probe giving the highest intensity at residue a identifies the substitution.
  • P 7 ⁇ P 7 4 the difference between the tiled reference sequence and the best-case match of the tiled array, exhibits 1's at positions 8 and 13 and 0's elsewhere, showing that substitutions have occurred at these two positions. Their identity is established by seeing which of the four nucleotides at these interrogation positions has the highest intensity.
  • probe arrays may be utilized to identify species of isolates.
  • generic it is meant that the probe array was not specifically designed to identify species within the genus of interest.
  • a probe array that includes all nucleic acid probes ten nucleotides in length would be a generic probe array.
  • a probe array for an entirely different purpose may be utilized as a generic probe array.
  • a probe array for detecting mutations in HIV may be utilized to identify species in Mycobacterium.
  • the isolates are first hybridized with the generic probe array to obtain hybridization intensities as described above. Typically, the hybridization intensities will then be normalized across the isolates. It has been determined that analyzing each hybridization intensity from the experiments may not be computationally feasible, or at least economically feasible. Accordingly, the invention reduces the number of variables to analyze.
  • the mean and variance for the hybridization intensities across the isolates is calculated.
  • the probes that demonstrate the most variance are then selected and the corresponding hybridization intensities are utilized to cluster the isolates into species.
  • the invention utilizes the hybridization intensities from probes that have the most varying hybridization intensities. One may first specify a number of probes which one believes could be processed by the equipment available. Then, the invention would select the hybridization intensities from that number of probes which will provide the most discriminating information.
  • This process may be generally utilized to assign groups to multiple isolates, where the groups are species, subspecies, phenotypes, genotypes, and the like. For illustration purposes, the following will describe an embodiment that identifies the species of isolates.
  • FIG. 35 shows a computer-implemented flowchart of a method of identifying species to which organisms belong.
  • hybridization intensities indicating hybridization affinity between multiple isolates and a generic probe array are input.
  • the hybridization intensities are then standardized or normalized at step 402 to reduce the variability between the experiments.
  • the hybridization intensities may be standardized to a common mean and variance by Z-score analysis or normalization.
  • the system selects hybridization intensities that have the most variance across the isolates at step 404 . Determining which hybridization intensities vary the most may be done any number of ways including calculating a mean and variance. As an example, the number of hybridization intensities to analyze may be reduced from 10,000 to 20 which drastically reduces the computational time required to analyze the hybridization intensities.
  • the species of each of the multiple isolates is determined according to the selected hybridization intensities.
  • Clustering algorithms may be utilized to cluster the isolates into species.
  • Principal Components analysis and Variable Clustering analysis may be utilized. The purpose of clustering is to place the isolates into groups or clusters suggested by the data, not defined a priori, such that isolates in a give cluster tend to be similar and isolates in different clusters tend to be dissimilar. Thus, no a prior classification is required.
  • FIG. 36 shows a hierarchical clustering of these isolates.
  • the height of the cluster represents the average distance between the clusters.
US08/797,812 1996-02-08 1997-02-07 Chip-based species identification and phenotypic characterization of microorganisms Expired - Lifetime US6228575B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US08/797,812 US6228575B1 (en) 1996-02-08 1997-02-07 Chip-based species identification and phenotypic characterization of microorganisms
US09/724,938 US6924094B1 (en) 1996-02-08 2000-11-28 Chip-based species identification and phenotypic characterization of microorganisms
US11/050,647 US7252948B2 (en) 1996-02-08 2005-02-04 Chip-based speciation and phenotypic characterization of microorganisms
US11/255,120 US20060177843A1 (en) 1996-02-08 2005-10-20 Bioarray chip reaction apparatus and its manufacture

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1133996P 1996-02-08 1996-02-08
US1263196P 1996-03-01 1996-03-01
US62903196A 1996-04-08 1996-04-08
US1776596P 1996-05-15 1996-05-15
US08/797,812 US6228575B1 (en) 1996-02-08 1997-02-07 Chip-based species identification and phenotypic characterization of microorganisms

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US62903196A Continuation-In-Part 1996-02-08 1996-04-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/724,938 Continuation US6924094B1 (en) 1996-02-08 2000-11-28 Chip-based species identification and phenotypic characterization of microorganisms

Publications (1)

Publication Number Publication Date
US6228575B1 true US6228575B1 (en) 2001-05-08

Family

ID=27486080

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/797,812 Expired - Lifetime US6228575B1 (en) 1996-02-08 1997-02-07 Chip-based species identification and phenotypic characterization of microorganisms

Country Status (5)

Country Link
US (1) US6228575B1 (fr)
EP (1) EP0937159A4 (fr)
JP (1) JP2000504575A (fr)
AU (1) AU2189397A (fr)
WO (1) WO1997029212A1 (fr)

Cited By (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012930A1 (en) * 1999-09-16 2002-01-31 Rothberg Jonathan M. Method of sequencing a nucleic acid
US20020025520A1 (en) * 1997-03-20 2002-02-28 Mark Chee Iterative resequencing
WO2002042485A2 (fr) * 2000-11-21 2002-05-30 Affymetrix, Inc. Procedes et progiciels permettant de choisir des sondes d'acides nucleiques
US20020106646A1 (en) * 2000-03-24 2002-08-08 Jose Remacle Identification of biological (micro) organisms by detection of their homologous nucleotide sequences on arrays
US20020110828A1 (en) * 2001-01-12 2002-08-15 Ferea Tracy L. Methods and compositions for microarray control
US20020150909A1 (en) * 1999-02-09 2002-10-17 Stuelpnagel John R. Automated information processing in randomly ordered arrays
US20020160401A1 (en) * 2001-03-29 2002-10-31 Yasuyuki Nozaki Biochip and method of designing probes
US20020164634A1 (en) * 2000-08-26 2002-11-07 Perlegen Sciences, Inc. Methods for reducing complexity of nucleic acid samples
US20020168648A1 (en) * 2000-08-31 2002-11-14 Nobuko Yamamoto Method for analyzing base sequence of nucleic acid
US20020187490A1 (en) * 2001-06-07 2002-12-12 Michigan State University Microbial identification chip based on DNA-DNA hybridization
US6516276B1 (en) * 1999-06-18 2003-02-04 Eos Biotechnology, Inc. Method and apparatus for analysis of data from biomolecular arrays
US20030027149A1 (en) * 2001-03-22 2003-02-06 David Dorris Ratio-based oligonucleotide probe selection
US6534266B1 (en) * 1999-04-22 2003-03-18 Albert Einstein College Of Medicine Of Yeshiva University Assay of transcription sites by multi-fluor fish
US20030059804A1 (en) * 2000-05-12 2003-03-27 Genemaster Lifescience Co., Ltd. Method for producing micro-carrier and test method by using said micro-carrier
US20030069701A1 (en) * 2001-05-29 2003-04-10 Toshiko Matsumoto Probe designing apparatus and probe designing method
US20030082569A1 (en) * 2001-03-13 2003-05-01 Johnson Clayton H. Histoplasma capsulatum catalase sequences and their use in the detection of Histoplasma capsulatum and Histoplasmosis
US20030096321A1 (en) * 1999-05-19 2003-05-22 Jose Remacle Method for the identification and/or the quantification of a target compound obtained from a biological sample upon chips
US20030099964A1 (en) * 2001-03-30 2003-05-29 Perlegen Sciences, Inc. Methods for genomic analysis
US20030108921A1 (en) * 2001-09-18 2003-06-12 Jucker Markus T. Detection of rpoB sequences of Mycobacterium tuberculosis
US20030113762A1 (en) * 2001-08-17 2003-06-19 Warrington Janet A. Gleason grade 4/5 prostate cancer genes
US6584410B2 (en) * 1997-08-15 2003-06-24 Affymetrix, Inc. Polymorphism detection utilizing clustering analysis
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
US20030157529A1 (en) * 2001-12-11 2003-08-21 Affymetrix, Inc. Methods for determining transcriptional activity
US20030157528A1 (en) * 2000-06-14 2003-08-21 Jose Remacle Reverse detection for identification and/or quantification of nucleotide target sequences on biochips
US20030157488A1 (en) * 2002-01-07 2003-08-21 Perlegen Sciences, Inc. Genetic analysis systems and methods
US20030198943A1 (en) * 2000-03-24 2003-10-23 Jose Remacle Identification of a large number of biological (micro)organisms groups at different levels by their detection on a same array
US20030224383A1 (en) * 2002-04-23 2003-12-04 Mike West Atherosclerotic phenotype determinative genes and methods for using the same
US20040029110A1 (en) * 1996-04-19 2004-02-12 Innogenetics N.V. Method for typing and detecting HBV
US20040053264A1 (en) * 2002-02-01 2004-03-18 Park Sung Sup Clinical panel assay using DNA chips
US20040092396A1 (en) * 1999-04-08 2004-05-13 Affymetrix, Inc. Porous silica substrates for polymer synthesis and assays
US20040157238A1 (en) * 2002-09-20 2004-08-12 Quinn John J. Method for detection of multiple nucleic acid sequence variations
EP1447454A1 (fr) * 2003-02-14 2004-08-18 DR. Chip Biotechnology Incorporation Procédé et appareil pour détecter des pathogènes
US20040196456A1 (en) * 1994-02-10 2004-10-07 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US20040197817A1 (en) * 1999-04-30 2004-10-07 Caren Michael P. Polynucleotide array fabrication
US20040248161A1 (en) * 1999-09-16 2004-12-09 Rothberg Jonathan M. Method of sequencing a nucleic acid
US20050032102A1 (en) * 2003-07-22 2005-02-10 Affymetrix, Inc. Mapping genomic rearrangements
US20050100911A1 (en) * 2003-08-06 2005-05-12 Perlegen Sciences, Inc. Methods for enriching populations of nucleic acid samples
US20050119473A1 (en) * 2000-03-17 2005-06-02 Affymetrix, Inc. Phosphite ester oxidation in nucleic acid array preparation
US6902894B2 (en) * 2001-09-07 2005-06-07 Genetel Pharmaceuticals Ltd. Mutation detection on RNA polmerase beta subunit gene having rifampin resistance
US20050123913A1 (en) * 2001-08-30 2005-06-09 Emory University Human mitochondrial dna polymorphisms, haplogroups, associations with physiological conditions, and genotyping arrays
US20050164274A1 (en) * 1996-06-25 2005-07-28 Michael Mecklenburg Broad specificity affinity arrays: a qualitative approach to complex sample discrimination
WO2005078131A1 (fr) * 2004-02-11 2005-08-25 Health Protection Agency Dosage de resistance a tb
US20050239104A1 (en) * 2003-11-04 2005-10-27 Ferea Tracy L Microarray controls
US20050250151A1 (en) * 2001-01-11 2005-11-10 Affymetrix, Inc. System, method, and computer software for genotyping analysis and identification of allelic imbalance
EP1595958A1 (fr) * 2004-05-10 2005-11-16 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Array specifique de Staphylococcus Aureus et Diagnostiques
EP1602735A2 (fr) * 2004-06-02 2005-12-07 Eppendorf Array Technologies S.A. Méthode et kit de détection et/ou de quantification de séquences nucléotidiques homologues sur un réseau
US20050282209A1 (en) * 2004-06-18 2005-12-22 Thomas Albert Variable length probe selection
US7005257B1 (en) * 1998-05-22 2006-02-28 Seapro Theranostics International Detection of antibiotic resistance in microorganisms
US20060051769A1 (en) * 2004-09-03 2006-03-09 Affymetrix, Inc. Methods of genetic analysis of E. coli
US20060099578A1 (en) * 2001-08-30 2006-05-11 Wallace Douglas C Mitochondrial biology expression arrays
US20060141493A1 (en) * 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
US20060147964A1 (en) * 1998-04-03 2006-07-06 Affymetrix, Inc. Mycobacterial rpoB sequences
US20060166224A1 (en) * 2005-01-24 2006-07-27 Norviel Vernon A Associations using genotypes and phenotypes
US20060183132A1 (en) * 2005-02-14 2006-08-17 Perlegen Sciences, Inc. Selection probe amplification
EP1693470A1 (fr) 2005-02-15 2006-08-23 Agilent Technologies, Inc. Méthodes et compositions pour la détermination de la cytotoxicité d'agents de transfection
WO2006094794A1 (fr) * 2005-03-11 2006-09-14 Eppendorf Ag Micromatrice avec commandes spécifiques de température
US20060210967A1 (en) * 2004-07-02 2006-09-21 Agan Brian K Re-sequencing pathogen microarray
US20060258002A1 (en) * 1997-12-11 2006-11-16 Affymetrix, Inc. Scanned image alignment systems and methods
US20070037187A1 (en) * 2000-03-24 2007-02-15 Isabelle Alexandre Identification and quantification of a plurality of biological (micro)organisms or their components
US7214492B1 (en) 2002-04-24 2007-05-08 The University Of North Carolina At Greensboro Nucleic acid arrays to monitor water and other ecosystems
US7217519B1 (en) 2002-11-21 2007-05-15 The Board Of Trustees Of The University Of Arkansas Histoplasma capsulatum chitin synthase sequences and their use for detection of Histoplasma capsulatum and histoplasmosis
US20070197911A1 (en) * 2006-01-27 2007-08-23 Affymetrix, Inc. System, Method, and Product for Imaging Probe Arrays with Small Feature Sizes
US20070211985A1 (en) * 2006-03-10 2007-09-13 Plc Diagnostics, Inc. Optical Scanning System
US20070292860A1 (en) * 2004-04-29 2007-12-20 Schuren Frank H J Staphylococcus Aureus Specific Diagnostics
US7321829B2 (en) * 1999-05-19 2008-01-22 Eppendorf Array Technologies (E.A.T.) Method for the identification and/or the quantification of a target compound obtained from a biological sample upon chips
AU2002323213B2 (en) * 2001-08-16 2008-03-13 Stratagene California Compositions and methods comprising control nucleic acid
US20080085515A1 (en) * 2000-03-24 2008-04-10 Eppendorf Array Technologies Sa (Eat) Identification of multiple biological (micro) organisms by detection of their nucleotide sequences on arrays
US20080206743A1 (en) * 2003-05-16 2008-08-28 Mark Barbour Rapid and Specific Detection of Enterobacter Sakazakii
US20080287308A1 (en) * 2007-05-18 2008-11-20 Affymetrix, Inc. System, method, and computer software product for genotype determination using probe array data
US7499806B2 (en) 2002-02-14 2009-03-03 Illumina, Inc. Image processing in microsphere arrays
US20090068668A1 (en) * 2007-09-12 2009-03-12 Plc Diagnostics, Inc. Waveguide-Based Optical Scanning Systems
US20090124514A1 (en) * 2003-02-26 2009-05-14 Perlegen Sciences, Inc. Selection probe amplification
US20090149340A1 (en) * 2007-06-25 2009-06-11 True Materials, Inc. Encoded microparticles
US20090264307A1 (en) * 2006-01-13 2009-10-22 The Trustees Of Princeton University Array-based polymorphism mapping at single nucleotide resolution
US20090291858A1 (en) * 2006-11-30 2009-11-26 The Regents Of The University Of California Array for detecting microbes
WO2010107825A2 (fr) 2009-03-16 2010-09-23 Pangu Biopharma Limited Compositions et procedes comprenant des variants d'epissage d'histidyl-arnt synthetase presentant des activites biologiques non canoniques
US20100255471A1 (en) * 2009-01-20 2010-10-07 Stanford University Single cell gene expression for diagnosis, prognosis and identification of drug targets
WO2010120509A2 (fr) 2009-03-31 2010-10-21 Atyr Pharma, Inc. Compositions et procédés impliquant des aspartyl-arnt synthétases présentant des activités biologiques non canoniques
US7829313B2 (en) 2000-03-24 2010-11-09 Eppendorf Array Technologies Identification and quantification of a plurality of biological (micro)organisms or their components
US20100302544A1 (en) * 2006-03-10 2010-12-02 Reuven Duer Waveguide-based detection system with scanning light source
US8048623B1 (en) 2002-04-24 2011-11-01 The University Of North Carolina At Greensboro Compositions, products, methods and systems to monitor water and other ecosystems
WO2011135459A2 (fr) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Méthodes et dispositifs permettant de prédire l'efficacité d'un traitement
WO2011140267A2 (fr) 2010-05-04 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de complexe multi-arnt synthétase p38
WO2011140135A2 (fr) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées des fragments protéiques de méthionyl-arnt-synthétases
WO2011139986A2 (fr) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à des fragments protéiques d'arginyle-arnt synthétases
WO2011139853A2 (fr) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Compositions thérapeutiques, diagnostiques et d'anticorps à base de fragments de protéines d'aminoacyl-arnt synthétases
WO2011140132A2 (fr) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de phénylalanyl-alpha-arnt-synthétases
WO2011139799A2 (fr) 2010-04-27 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps se rapportant à des fragments protéiques d'isoleucyl arnt synthétases
WO2011139714A2 (fr) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps se rapportant à des fragments protéiques de la cystéinyl-arnt synthétase
WO2011139907A2 (fr) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Découverte innovatrice de compositions thérapeutiques, diagnostiques, et d'anticorps associées aux fragments protéiques des valyle arnt synthésases
WO2011139854A2 (fr) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à based'anticorps associées à des fragments protéiques d'asparaginyl-arnt-synthétases
WO2011143482A2 (fr) 2010-05-14 2011-11-17 Atyr Pharma, Inc. Découverte de compositions inédites de nature thérapeutique, diagnostique et à base d'anticorps contenant des fragments protéiques de phénylalanyl-bêta-arnt synthétases
WO2011146410A2 (fr) 2010-05-17 2011-11-24 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic, et d'anticorps associées à des fragments protéiques de leucyl-arnt synthétases
WO2011150279A2 (fr) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à fragments protéiques de glutaminyl-arnt synthétases
WO2011153277A2 (fr) 2010-06-01 2011-12-08 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques, et d'anticorps associés à des fragments de protéine de lysyl-tarn synthétases
WO2012021247A2 (fr) 2010-07-12 2012-02-16 Atyr Pharma, Inc. DÉCOUVERTE INNOVANTE DE COMPOSITIONS THÉRAPEUTIQUES, DE DIAGNOSTIC ET D'ANTICORPS SE RAPPORTANT À DES FRAGMENTS PROTÉIQUES DE GLYCYL-ARNt SYNTHÉTASES
WO2012027611A2 (fr) 2010-08-25 2012-03-01 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et d'anticorps associées à des fragments protéiniques des tyrosyl-arnt synthétases
WO2012037378A2 (fr) 2010-09-15 2012-03-22 Almac Diagnostics Limited Test de diagnostic moléculaire du cancer
US8233735B2 (en) 1994-02-10 2012-07-31 Affymetrix, Inc. Methods and apparatus for detection of fluorescently labeled materials
WO2012163541A1 (fr) 2011-06-01 2012-12-06 Medical Prognosis Institute A/S Procédés et dispositifs pour le pronostic d'une rechute du cancer
US8383342B2 (en) 2002-04-24 2013-02-26 The University Of North Carolina At Greensboro Compositions, products, methods and systems to monitor water and other ecosystems
EP2604703A2 (fr) 2005-03-14 2013-06-19 The Board of Trustees of Leland Stanford Junior University Procédés permettant d'évaluer la survie d'un greffon chez un destinataire d'une transplantation d'organe solide
WO2013123432A2 (fr) 2012-02-16 2013-08-22 Atyr Pharma, Inc. Histidyl-arnt synthétases pour le traitement de maladies auto-immunes et inflammatoires
EP2631301A1 (fr) 2008-08-18 2013-08-28 The Board of Trustees of the Leland Stanford Junior University Procédés et compositions pour déterminer un phénotype tolérant à une greffe chez un sujet
WO2014085434A1 (fr) 2012-11-27 2014-06-05 Pontificia Universidad Catolica De Chile Compositions et procédés de diagnostic de tumeurs de la thyroïde
US8747751B2 (en) 2008-06-16 2014-06-10 Plc Diagnostics, Inc. System and method for nucleic acids sequencing by phased synthesis
WO2014148780A1 (fr) 2013-03-20 2014-09-25 서울대학교산학협력단 Biomarqueur pour le diagnostic du cancer du foie
EP2803735A1 (fr) 2010-03-25 2014-11-19 The Board Of Trustees Of The Leland Stanford Junior University Biomarqueurs de protéines et de gènes pour le rejet d'organes transplantés
WO2014195032A1 (fr) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Procédés et dispositifs pour prédire une efficacité de traitement de fulvestrant chez des patients atteints de cancer
WO2015023068A1 (fr) 2013-08-13 2015-02-19 서울대학교산학협력단 Procédé de criblage de marqueur de cancer par l'intermédiaire d'une détection de déglycosylation de glycoprotéine et de marqueur de cancer hépatocellulaire
US9126165B1 (en) 2002-04-24 2015-09-08 The University Of North Carolina At Greensboro Nucleic acid arrays to monitor water and other ecosystems
WO2016008048A1 (fr) 2014-07-15 2016-01-21 Ontario Institute For Cancer Research Procédés et dispositifs permettant de prédire l'efficacité d'un traitement à l'anthracycline
EP2993473A1 (fr) 2007-01-30 2016-03-09 Pharmacyclics, Inc. Procédés permettant de déterminer la résistance du cancer aux inhibiteurs de l'histone désacétylase
US20160083793A1 (en) * 2014-08-19 2016-03-24 Joshua Labaer Radiation biodosimetry systems
US9423397B2 (en) 2006-03-10 2016-08-23 Indx Lifecare, Inc. Waveguide-based detection system with scanning light source
US9445025B2 (en) 2006-01-27 2016-09-13 Affymetrix, Inc. System, method, and product for imaging probe arrays with small feature sizes
US9528939B2 (en) 2006-03-10 2016-12-27 Indx Lifecare, Inc. Waveguide-based optical scanning systems
WO2017013436A1 (fr) 2015-07-21 2017-01-26 Almac Diagnostics Limited Signature génique pour immunothérapies dans le cancer
EP3185013A2 (fr) 2009-12-02 2017-06-28 The Board of Trustees of the Leland Stanford Junior University Biomarqueurs pour déterminer un xénotype tolérant à l'allogreffe
WO2017181367A1 (fr) 2016-04-20 2017-10-26 Ldx Prognostics Limited Co. Procédés et compositions pour pronostiquer une naissance prématurée
WO2017197573A1 (fr) 2016-05-17 2017-11-23 Ldx Prognostics Limited Co. Méthodes et compositions pour fournir une évaluation de la prééclampsie
US9976192B2 (en) 2006-03-10 2018-05-22 Ldip, Llc Waveguide-based detection system with scanning light source
US10018566B2 (en) 2014-02-28 2018-07-10 Ldip, Llc Partially encapsulated waveguide based sensing chips, systems and methods of use
WO2018208091A2 (fr) 2017-05-10 2018-11-15 서울대학교산학협력단 Biomarqueur permettant de surveiller ou de diagnostiquer l'apparition d'un cancer du foie dans un groupe fortement exposé à un cancer du foie et son utilisation
US11181479B2 (en) 2015-02-27 2021-11-23 Ldip, Llc Waveguide-based detection system with scanning light source

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270961B1 (en) * 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US20020048749A1 (en) * 1998-04-15 2002-04-25 Robert J. Lipshutz Methods for polymorphism identifcation and profiling
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
US6953663B1 (en) 1995-11-29 2005-10-11 Affymetrix, Inc. Polymorphism detection
US6965020B2 (en) 1996-01-23 2005-11-15 Affymetrix, Inc. Nucleic acid labeling compounds
US20010018514A1 (en) 1998-07-31 2001-08-30 Mcgall Glenn H. Nucleic acid labeling compounds
US7423143B2 (en) 1996-01-23 2008-09-09 Affymetrix. Inc. Nucleic acid labeling compounds
US7282327B2 (en) 1996-01-23 2007-10-16 Affymetrix, Inc. Nucleic acid labeling compounds
US6864059B2 (en) 1996-01-23 2005-03-08 Affymetrix, Inc. Biotin containing C-glycoside nucleic acid labeling compounds
FR2775984B1 (fr) 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
US6881571B1 (en) 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
US6391550B1 (en) 1996-09-19 2002-05-21 Affymetrix, Inc. Identification of molecular sequence signatures and methods involving the same
US6458584B1 (en) * 1996-12-23 2002-10-01 University Of Chicago Customized oligonucleotide microchips that convert multiple genetic information to simple patterns, are portable and reusable
US20020042048A1 (en) 1997-01-16 2002-04-11 Radoje Drmanac Methods and compositions for detection or quantification of nucleic acid species
NO972006D0 (no) 1997-04-30 1997-04-30 Forskningsparken I Aas As Ny metode for diagnose av sykdommer
US7068830B2 (en) 1997-07-25 2006-06-27 Affymetrix, Inc. Method and system for providing a probe array chip design database
US6420108B2 (en) 1998-02-09 2002-07-16 Affymetrix, Inc. Computer-aided display for comparative gene expression
WO1999005324A1 (fr) 1997-07-25 1999-02-04 Affymetrix, Inc. SYSTEME D'OBTENTION D'UNE BASE DE DONNEES DE POLYMORPHISMES$i()
US6826296B2 (en) 1997-07-25 2004-11-30 Affymetrix, Inc. Method and system for providing a probe array chip design database
WO1999014369A1 (fr) * 1997-09-05 1999-03-25 Affymetrix, Inc. Techniques permettant d'identifier, confirmer, cartographier et classer des polymeres
US7099777B1 (en) 1997-09-05 2006-08-29 Affymetrix, Inc. Techniques for identifying confirming mapping and categorizing nucleic acids
US6289229B1 (en) 1998-01-20 2001-09-11 Scimed Life Systems, Inc. Readable probe array for in vivo use
US6187535B1 (en) 1998-02-18 2001-02-13 Institut Pasteur Fast and exhaustive method for selecting a prey polypeptide interacting with a bait polypeptide of interest: application to the construction of maps of interactors polypeptides
US6324479B1 (en) * 1998-05-08 2001-11-27 Rosetta Impharmatics, Inc. Methods of determining protein activity levels using gene expression profiles
US6699659B2 (en) * 1998-06-01 2004-03-02 Affymetrix, Inc. Products and methods for analyzing nucleic acids including identification of substitutions, insertions and deletions
CA2273616A1 (fr) * 1998-06-08 1999-12-08 The Board Of Trustees Of The Leland Stanford Junior University Methode de detection parallele de variation allelique
US6185561B1 (en) 1998-09-17 2001-02-06 Affymetrix, Inc. Method and apparatus for providing and expression data mining database
US6703228B1 (en) 1998-09-25 2004-03-09 Massachusetts Institute Of Technology Methods and products related to genotyping and DNA analysis
US6203989B1 (en) 1998-09-30 2001-03-20 Affymetrix, Inc. Methods and compositions for amplifying detectable signals in specific binding assays
US6489096B1 (en) 1998-10-15 2002-12-03 Princeton University Quantitative analysis of hybridization patterns and intensities in oligonucleotide arrays
US6670464B1 (en) 1998-11-17 2003-12-30 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
FR2791067B1 (fr) 1999-03-16 2003-01-31 Pasteur Institut Sequence deletees chez m.bovis bcg/m.ou m.tuberculosis, procede de detection des mycobacteries utilisant ces sequences et vaccins
AU3444300A (en) * 1999-03-24 2000-10-09 Clatterbridge Cancer Research Trust Genetic analysis
GB9906833D0 (en) * 1999-03-24 1999-05-19 Clatterbridge Cancer Res Trust Genetic analysis
EP1925678B1 (fr) * 1999-05-03 2009-07-22 Gen-Probe Incorporated Procédé à base de matrice de polynucléotides pour identifier des microorganismes
US6821770B1 (en) 1999-05-03 2004-11-23 Gen-Probe Incorporated Polynucleotide matrix-based method of identifying microorganisms
DE60042623D1 (de) * 1999-05-03 2009-09-03 Gen Probe Inc Polynukleotidmatrix-basiertes Verfahren zur Identifizierung von Mikroorganismen
WO2000075377A2 (fr) * 1999-06-03 2000-12-14 Jacques Schrenzel Systeme d'hybridation non cognat (nchs)
EP1076099A3 (fr) * 1999-08-03 2003-03-05 Nisshinbo Industries, Inc. Trousse pour la diagnose des bacilles de tubercule
IL131324A (en) * 1999-08-10 2004-01-04 Compugen Ltd Nucleic acid analysis method and system
EP1078993A1 (fr) * 1999-08-24 2001-02-28 Biomerieux Procédé d'analyse de mesures effectuées sur une biopuce
EP2319939A3 (fr) 1999-10-21 2012-09-26 Case Western Reserve University Profilage d'expression de gènes de maladie intestinale inflammatoire
EP1096024A1 (fr) * 1999-10-28 2001-05-02 Remacle, José Méthode et trousse pour le criblage et/ou la quantification de séquences d' acides nucléiques multiples homologues avec des ensembles de sondes
DE10000629C5 (de) * 2000-01-10 2010-06-02 november Aktiengesellschaft, Gesellschaft für Molekulare Medizin Verfahren zur Identifizierung einer auf einen festen Körper aufgebrachten Markierung
EP1136566A1 (fr) * 2000-03-24 2001-09-26 Facultés Universitaires Notre-Dame de la Paix Procédé et trousse pour la détection et/ou la quantification d'acides nucléiques homologues par un ensemble d'ADN
CA2403874A1 (fr) 2000-03-28 2001-12-06 Dana-Farber Cancer Institute, Inc. Base de donnees moleculaire pour la caracterisation d'anticorps
KR100451108B1 (ko) * 2000-05-30 2004-10-06 주식회사 바이오메드랩 마이코박테리아 균동정 및 약제내성 탐지를 위한 유전자진단키트 및 그 키트의 제조방법
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
ES2398391T3 (es) 2000-06-15 2013-03-15 Novartis Vaccines And Diagnostics, Inc. Polinucleótidos relacionados con cáncer de colon
EP1373563B1 (fr) * 2000-07-21 2006-03-29 Université d'Auvergne Procede de detection de microorganismes
FR2814756B1 (fr) * 2000-10-02 2004-11-19 Univ Clermont Auvergne Procede de detection de microorganismes
EP2332574A1 (fr) 2000-08-17 2011-06-15 Tripep Ab Séquences de HCV NS3/4A
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
WO2002046477A2 (fr) 2000-12-07 2002-06-13 Chiron Corporation Retrovirus endogenes regules positivement dans le cancer de la prostate
JP2002209584A (ja) * 2001-01-16 2002-07-30 Toyobo Co Ltd 塩基多型を検出する方法
FR2819524B1 (fr) * 2001-01-18 2003-07-04 Antonios Vekris Hybridation differentielle par competition
EP1385829A4 (fr) 2001-03-12 2005-10-19 Affymetrix Inc Composes de marquage d'acide nucleique
EP1925672A1 (fr) 2001-06-22 2008-05-28 Syngeta Participations AG Polynucléotides et polypeptides sensibles au stress abiotique
WO2003014151A2 (fr) 2001-08-10 2003-02-20 Genset S.A. Adn complementaire et proteines humains et leurs utilisations
KR100454585B1 (ko) * 2001-10-09 2004-11-02 주식회사 에스제이하이테크 마이코박테리아의 균주 감별, 결핵균의 스트레인 감별과항생제 내성을 검출하기 위한 프로브를 포함하는마이크로어레이와 이를 이용한 검출 방법 및 진단 키트
US7498407B2 (en) 2001-11-09 2009-03-03 Georgetown University Vascular endothelial cell growth inhibitor, VEGI-192a
DE60326931D1 (de) 2002-01-08 2009-05-14 Novartis Vaccines & Diagnostic In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
EP1365034A3 (fr) 2002-05-21 2004-02-18 Bayer HealthCare AG Procédés et compositions pour la prédiction, le diagnostic, le pronostic, la prévention et le traitement de neoplasie maligne
AU2003276679A1 (en) 2002-06-13 2003-12-31 Chiron Corporation Vectors for expression of hml-2 polypeptides
JP4579577B2 (ja) * 2003-05-19 2010-11-10 キヤノン株式会社 情報処理装置および情報処理方法ならびに記憶媒体、プログラム
CA2528025A1 (fr) * 2003-06-05 2005-02-17 Wyeth Groupe d'acides nucleiques servant a detecter des souches multiples d'especes non virales
EP1892306A3 (fr) 2003-10-06 2008-06-11 Bayer HealthCare AG Méthode et trousses pour évaluer un cancer
WO2005035788A2 (fr) 2003-10-10 2005-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Procede et kit d'evaluation de l'anxiete ou de disposition a l'anxiete chez un sujet
EP1756303B1 (fr) 2004-04-09 2010-12-08 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Outil diagnostique permettant de diagnostiquer des lesions thyroidiennes benignes contre des lesions thyroidiennes malignes
GB0412301D0 (en) 2004-06-02 2004-07-07 Diagenic As Product and method
FI20041204A0 (fi) 2004-09-16 2004-09-16 Riikka Lund Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
SG156690A1 (en) 2004-10-27 2009-11-26 Univ Vanderbilt Mammalian genes involved in infection
EP1724360A1 (fr) * 2005-05-17 2006-11-22 Eppendorf Array Technologies S.A. Méthode d'identification ou quantification d'éléments de séquences nucléotidiques spécifiques de plants modifiés génétiquement
US7968697B2 (en) 2005-05-25 2011-06-28 Chrontech Pharma Ab Hepatitis C virus non-structural NS3/4A fusion gene
WO2007016367A2 (fr) 2005-07-29 2007-02-08 Bayer Healthcare Llc Procedes, kits, systemes et bases de donnees relatifs a des maladies neoplasiques
EP1762628B1 (fr) 2005-09-13 2008-03-12 Eppendorf Array Technologies SA Procédé pour la détection sur un micro-reseau de sequences homologues différent par une base
CA2657576C (fr) 2006-07-14 2023-10-31 The Regents Of The University Of California Biomarqueurs du cancer et methodes d'utilisation associees
DK2121977T3 (en) 2007-01-11 2017-09-18 Erasmus Univ Medical Center Capture (4C) OF CHROMOSOMES WITH CIRCULAR CONFORMATION
EP2185195A2 (fr) 2007-08-16 2010-05-19 Tripep Ab Plate-forme immunogène
US9234244B2 (en) 2007-08-27 2016-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnostic tool for diagnosing benign versus malignant thyroid lesions
WO2009039466A1 (fr) 2007-09-20 2009-03-26 Vanderbilt University Mesure de solution libre d'interactions moléculaires par interférométrie rétrodiffusée
EP2300041B1 (fr) 2008-04-16 2016-01-27 The Johns Hopkins University Méthode pour déterminer le risque du récidive du cancer de la prostate
CA2721503A1 (fr) 2008-04-18 2009-12-03 Massachusetts General Hospital Polymorphismes associes a la degenerescence maculaire liee a l'age et procedes d'evaluation du risque pour un patient
AU2010229767C1 (en) 2009-03-27 2015-02-19 The General Hospital Corporation Markers related to age-related macular degeneration and uses therefor
US20120003639A1 (en) 2010-04-27 2012-01-05 Prelude, Inc. Cancer biomarkers and methods of use thereof
WO2011146725A1 (fr) 2010-05-19 2011-11-24 Bayer Healthcare Llc Biomarqueurs pour un inhibiteur à multiples kinases
WO2011156713A1 (fr) 2010-06-11 2011-12-15 Vanderbilt University Système et procédé de détection interférométrique multiplexés
US10202615B2 (en) 2010-12-10 2019-02-12 Vanderbilt University Mammalian genes involved in toxicity and infection
WO2012090073A2 (fr) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Procédés et compositions pour prédire la sensibilité à la chimiothérapie
US9335289B2 (en) 2011-02-07 2016-05-10 The Governing Council Of The University Of Toronto Bioprobes and methods of use thereof
US9562853B2 (en) 2011-02-22 2017-02-07 Vanderbilt University Nonaqueous backscattering interferometric methods
US9051619B2 (en) 2011-03-25 2015-06-09 Florida Agricultural and Mechanical University (FAMU) Methods and compositions for prostate cancer metastasis
EP2694678A2 (fr) 2011-04-04 2014-02-12 Netherland Cancer Institute Procédés et compositions pour prédire une résistance à un traitement anti-cancéreux
WO2012138783A2 (fr) 2011-04-04 2012-10-11 Netherlands Cancer Institute Procédés et compositions pour prédire une résistance à un traitement anti-cancéreux
EP2701736A1 (fr) 2011-04-25 2014-03-05 Advanced Bioscience Laboratories, Inc. Protéines tronquées d'enveloppe (env) du vih, procédés et compositions associés à celles-ci
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
WO2012154994A2 (fr) 2011-05-10 2012-11-15 The Regents Of The University Of Californa Nouvel adénovirus isolé de singes marmousets
US9273949B2 (en) 2012-05-11 2016-03-01 Vanderbilt University Backscattering interferometric methods
CN108624668B (zh) 2013-02-01 2022-12-02 加利福尼亚大学董事会 用于基因组组装及单体型定相的方法
US9411930B2 (en) 2013-02-01 2016-08-09 The Regents Of The University Of California Methods for genome assembly and haplotype phasing
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
CN105392882A (zh) 2013-04-19 2016-03-09 加利福尼亚大学董事会 孤星病毒
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
WO2015179404A1 (fr) 2014-05-19 2015-11-26 The Johns Hopkins University Procédés d'identification de variants d'épissage du récepteur des androgènes chez des sujets présentant un cancer de la prostate résistant à la castration
AU2015296029B2 (en) 2014-08-01 2022-01-27 Dovetail Genomics, Llc Tagging nucleic acids for sequence assembly
WO2016033114A1 (fr) 2014-08-25 2016-03-03 The Johns Hopkins University Procédés et compositions associés à des thérapies du cancer de la prostate
CN107427515B (zh) 2014-12-03 2021-11-16 奥克兰联合服务有限公司 用于治疗癌症的激酶抑制剂前药
EP3227687A4 (fr) 2014-12-05 2018-10-24 Prelude, Inc. Récurrence de carcinome canalaire in situ (dcis) et cancer du sein invasif
WO2016118812A1 (fr) 2015-01-23 2016-07-28 Vanderbilt University Interféromètre robuste et procédés de son utilisation
SG11201706730XA (en) 2015-02-17 2017-09-28 Dovetail Genomics Llc Nucleic acid sequence assembly
GB2554572B (en) 2015-03-26 2021-06-23 Dovetail Genomics Llc Physical linkage preservation in DNA storage
EP4019643A1 (fr) 2015-09-23 2022-06-29 Oklahoma Medical Research Foundation Biomarqueurs permettant d'évaluer des sujets présentant une sclérose en plaques
AU2016341198B2 (en) 2015-10-19 2023-03-09 Dovetail Genomics, Llc Methods for genome assembly, haplotype phasing, and target independent nucleic acid detection
EP3387154A4 (fr) 2015-12-09 2019-05-15 Intuitive Biosciences, Inc. Système automatisé d'amélioration d'argent
US10627396B2 (en) 2016-01-29 2020-04-21 Vanderbilt University Free-solution response function interferometry
KR20180116377A (ko) 2016-02-23 2018-10-24 더브테일 제노믹스 엘엘씨 게놈 어셈블리를 위한 페이징된 판독 세트의 생성 및 반수체형 페이징
IL262946B2 (en) 2016-05-13 2023-03-01 Dovetail Genomics Llc Retrieving long-range grip information from preserved samples
JP2022500504A (ja) 2018-09-14 2022-01-04 プレリュード コーポレーションPrelude Corporation 浸潤性乳癌のリスクを有する対象の治療の選択方法

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
WO1989010977A1 (fr) * 1988-05-03 1989-11-16 Isis Innovation Limited Analyse de sequences de polynucleotides
WO1990015070A1 (fr) 1989-06-07 1990-12-13 Affymax Technologies N.V. Synthese a grande echelle de peptides immobilises
WO1992010092A1 (fr) 1990-12-06 1992-06-25 Affymax Technologies N.V. Synthese de polymeres immobilises sur tres grande echelle
WO1994012305A1 (fr) 1992-11-23 1994-06-09 Gühring, Jörg Outil de forage a piece de coupe rapportee interchangeable
WO1995011995A1 (fr) 1993-10-26 1995-05-04 Affymax Technologies N.V. Reseaux de sondes d'acide nucleique sur des microplaquettes biologiques
US5429807A (en) * 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US5436327A (en) * 1988-09-21 1995-07-25 Isis Innovation Limited Support-bound oligonucleotides
US5545531A (en) * 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5795716A (en) * 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5861242A (en) * 1993-06-25 1999-01-19 Affymetrix, Inc. Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132843T2 (de) * 1990-12-06 2002-09-12 Affymetrix Inc N D Ges D Staat Identifizierung von Nukleinsäuren in Proben
IL103674A0 (en) * 1991-11-19 1993-04-04 Houston Advanced Res Center Method and apparatus for molecule detection

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4366241B1 (fr) 1980-08-07 1988-10-18
WO1989010977A1 (fr) * 1988-05-03 1989-11-16 Isis Innovation Limited Analyse de sequences de polynucleotides
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5436327A (en) * 1988-09-21 1995-07-25 Isis Innovation Limited Support-bound oligonucleotides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
WO1990015070A1 (fr) 1989-06-07 1990-12-13 Affymax Technologies N.V. Synthese a grande echelle de peptides immobilises
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
WO1992010092A1 (fr) 1990-12-06 1992-06-25 Affymax Technologies N.V. Synthese de polymeres immobilises sur tres grande echelle
WO1994012305A1 (fr) 1992-11-23 1994-06-09 Gühring, Jörg Outil de forage a piece de coupe rapportee interchangeable
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5861242A (en) * 1993-06-25 1999-01-19 Affymetrix, Inc. Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same
WO1995011995A1 (fr) 1993-10-26 1995-05-04 Affymax Technologies N.V. Reseaux de sondes d'acide nucleique sur des microplaquettes biologiques
US5429807A (en) * 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US5795716A (en) * 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5545531A (en) * 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
Barringer, K.J. et al., "Blunt-end and single-strand ligations by Escherichia coli ligase: influence on an in vitro amplification scheme," Gene 89:117-122 (1990).*
Bloch, A.B. et al., "Nationwide Survey of Drug-Resistant Tuberculosis in the United States," J. Amer. Med. Assoc. 271(9):665-671 (1994).*
Chetverin et al., Bio/Technology 12, 1093-1099, 1994.*
E.M. Southern et al. "Analyzing and Comparing Nucleic Acid Sequences by Hybridization to Arrays of Oligonucleotides: Evaluation Using Experimental Models" Genomics (1992) 13:1008-1017.*
Fodor, S.P.A. et al., "Light-Directed Spatially Addressable Parallel Chemical Synthesis," Science 251:767-773 (1991).*
Fodor, S.P.A. et al., "Multiplexed biochemical assays with biological chips," Nature 364:555-556 (1993).*
Guatelli, J.C. et al., "Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication," Proc. Natl. Acad. Sci. U.S.A. 87:1874-1878 (1990).*
Hoffner, S.E., "Pulmonary Infections Caused by Less Frequently Encountered Slow-Growing Environmental Mycobacteria," Eur. J. Clin. Microbiol. Infect. Dis. 13(11): 937-941 (1994).*
Hunt, J.M. et al., "Detection of a Genetic Locus encoding Resistance to Rifampin in Mycobacterial Cultures and in Clinical Specimens," Diagn. Microbiol. Infect. Dis. 18:219-227 (1994).*
J.K. Elder "Analysis of DNA Oligonucleotide Hybridization Data by Maximum Entropy" in Proceedings of the Twelfth Internation Workshop on Maximum Entropy and Bayesian Methods, (1992), A. Mohammad-Djafari and G. Demoment eds., Kluwer Academic Publishers, Dordrecht.*
Jonas, V. et al., "Detection and Identification of Mycobacterium tuberculosis Directly from Sputum Sediments by Amplification of rRNA," J. Clin. Microbiol. 31(9):2410-2416 (1993).*
Kanal, L., "Patterns in Pattern Recognition: 1968-1974," IEEE Trans. Info. Theory IT-20(6):697-722 (1974).*
Kapur, V. et al., "Rapid Mycobacterium Species Assignment and Unambiguous Identification of Mutations Associated with Antimicrobial Resistance in Mycobacterium tuberculosis by Automated DNA Sequencing," Arch. Path. Lab. Med. 119:131-138 (1995).*
Kox, L.F.F. et al., "PCR Assay Based on DNA Coding for 16S rRNA for Detection and Identification of Mycobacteria in Clinical Samples," J. Clin. Microbiol. 33(12):3225-3233 (1995).*
Kwoh, D.Y. et al., "Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format," Proc. Natl. Acad. Sci. U.S.A. 86:1173-1177 (1989).*
Landegren, U. et al., "A Ligase-Mediated Gene Detection Technique," Science 241:1077-1080 (1988).*
Lipshutz, Clin. Chem. 40(6), 1173 (abstract), 1994.*
Lipshutz, R.J. et al., "Using Oligonucleotide Probe Arrays to Access Genetic Diversity," Biotechniques 19(3):442-447 (1995).*
Musser, J.M., "Antimicrobial Agent Resistance in Mycobacteria: Molecular Genetic Insights," Clin. Microbiol. Rev. 8(4):496-514 (1995).*
Pease, A.C. et al., "Light-generated oligonucleotide arrays for rapid DNA sequence analysis," Proc. Natl. Acad. Sci. U.S.A. 91:5022-5026 (1994).*
Salazar et al., Nucleic Acids Res. 24(24), 5056-5057, 1996.*
Schirm, J. et al., "Comparison of Amplicor, In-House PCR, and Conventional Culture for Detection of Mycobacterium tuberculosis in Clinical Samples," J. Clin. Microbiol. 33(12):3221-3224 (1995).*
Sewell, D.L. et al., "Comparison of the Septi-Chek AFB and BACTEC Systems and Conventional Culture for Recovery of Mycobacteria," J. Clin. Microbiol. 31(10):2689-2691 (1993).*
Shafer, R.W. et al., "Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and Other Nontuberculous Mycobacteria in an Area of Endemicity for AIDS," Clin. Infect. Dis. 15:161-162 (1992).*
Small, P.M. et al., "Molecular Epidemiology of Tuberculosis," Tuberculosis: Pathogenesis, Protection, and Control, Bloom, B.R., ed., Amer. Soc. Microbiol., Chapter 33, pp. 569-582 (1994).*
Stager, C.E. et al., "Role of Solid Media When Used in Conjunction with the BACTEC System for Mycobacterial Isolation and Identification," J. Clin. Microbiol. 29(1):154-157 (1991).*
Telenti, A. et al., "Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis," Lancet 341:647-650 (1993).*
U.S. application No. 07/624,114, Fodor et al., filed Dec. 6, 1990.*
U.S. application No. 08/082,937, Fodor et al., filed Jun. 25, 1993.*
U.S. application No. 08/168,904, Fodor et al., filed Dec. 15, 1993.*
U.S. application No. 08/505,919, Fodor et al., filed Jul. 24, 1995.*
U.S. application No. 08/811,829, Fodor et al., filed Mar. 5, 1997.*
U.S. application No. 08/829,893, Dower et al., filed Apr. 2, 1997. *
U.S. application No. 08/873,034, Fodor et al., filed Jun. 11, 1997.*
U.S. application No. 08/887,196, Fodor et al., filed Jun. 17, 1997.*
Wolinsky, E., "Mycobacterial Diseases Other Than Tuberculosis," Clin. Infect. Dis. 15:1-12 (1992).*
Wu, D.Y. et al., "The Ligation Amplification reaction (LAR)-Amplification of Specific DNA Sequences Using Sequential Rounds of Template-Dependent Ligation," Genomics 4:560-569 (1989).*

Cited By (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060111850A1 (en) * 1994-02-10 2006-05-25 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US8233735B2 (en) 1994-02-10 2012-07-31 Affymetrix, Inc. Methods and apparatus for detection of fluorescently labeled materials
US20040196456A1 (en) * 1994-02-10 2004-10-07 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US20060105363A1 (en) * 1995-09-15 2006-05-18 Affymetrix, Inc. Methods for determining transcriptional activity
US7313357B2 (en) 1996-04-19 2007-12-25 Innogenetics N.V. Method for typing and detecting HBV
US6709812B1 (en) * 1996-04-19 2004-03-23 Innogenetics N.V. Method for typing and detecting HBV
US8859203B2 (en) 1996-04-19 2014-10-14 Fujirebio Europe N.V. Method for typing and detecting HBV
US20040029110A1 (en) * 1996-04-19 2004-02-12 Innogenetics N.V. Method for typing and detecting HBV
US20090197244A1 (en) * 1996-04-19 2009-08-06 Innogenetics N.V. Method for typing and detecting HBV
US8835106B2 (en) 1996-04-19 2014-09-16 Fujirebio Europe N.V. Method for typing and detecting HBV
US20110111973A1 (en) * 1996-06-25 2011-05-12 Michael Mecklenburg Broad specificity affinity arrays: a qualitative approach to complex sample discrimination
US20050164274A1 (en) * 1996-06-25 2005-07-28 Michael Mecklenburg Broad specificity affinity arrays: a qualitative approach to complex sample discrimination
US7662560B2 (en) 1996-06-25 2010-02-16 Michael Mecklenburg Broad specificity affinity arrays: a qualitative approach to complex sample discrimination
US7144699B2 (en) * 1997-03-20 2006-12-05 Affymetrix, Inc. Iterative resequencing
US20020025520A1 (en) * 1997-03-20 2002-02-28 Mark Chee Iterative resequencing
US6584410B2 (en) * 1997-08-15 2003-06-24 Affymetrix, Inc. Polymorphism detection utilizing clustering analysis
US20040024537A1 (en) * 1997-08-15 2004-02-05 Affymetrix, Inc. A Corporation Of The State Of California Polymorphism detection utilizing clustering analysis
US20060258002A1 (en) * 1997-12-11 2006-11-16 Affymetrix, Inc. Scanned image alignment systems and methods
US20060147964A1 (en) * 1998-04-03 2006-07-06 Affymetrix, Inc. Mycobacterial rpoB sequences
US7005257B1 (en) * 1998-05-22 2006-02-28 Seapro Theranostics International Detection of antibiotic resistance in microorganisms
US20020150909A1 (en) * 1999-02-09 2002-10-17 Stuelpnagel John R. Automated information processing in randomly ordered arrays
US6824866B1 (en) 1999-04-08 2004-11-30 Affymetrix, Inc. Porous silica substrates for polymer synthesis and assays
US20040092396A1 (en) * 1999-04-08 2004-05-13 Affymetrix, Inc. Porous silica substrates for polymer synthesis and assays
US6534266B1 (en) * 1999-04-22 2003-03-18 Albert Einstein College Of Medicine Of Yeshiva University Assay of transcription sites by multi-fluor fish
US20040197817A1 (en) * 1999-04-30 2004-10-07 Caren Michael P. Polynucleotide array fabrication
US20040203047A1 (en) * 1999-04-30 2004-10-14 Caren Michael P. Polynucleotide array fabrication
US20040203138A1 (en) * 1999-04-30 2004-10-14 Caren Michael P. Polynucleotide array fabrication
US20030096321A1 (en) * 1999-05-19 2003-05-22 Jose Remacle Method for the identification and/or the quantification of a target compound obtained from a biological sample upon chips
US20100113301A1 (en) * 1999-05-19 2010-05-06 Eppendorf Array Technologies Method for the identification and/or the quantification of a target compound obtained from a biological sample upon chips
US7321829B2 (en) * 1999-05-19 2008-01-22 Eppendorf Array Technologies (E.A.T.) Method for the identification and/or the quantification of a target compound obtained from a biological sample upon chips
US6516276B1 (en) * 1999-06-18 2003-02-04 Eos Biotechnology, Inc. Method and apparatus for analysis of data from biomolecular arrays
US20020012930A1 (en) * 1999-09-16 2002-01-31 Rothberg Jonathan M. Method of sequencing a nucleic acid
US7211390B2 (en) 1999-09-16 2007-05-01 454 Life Sciences Corporation Method of sequencing a nucleic acid
US7335762B2 (en) 1999-09-16 2008-02-26 454 Life Sciences Corporation Apparatus and method for sequencing a nucleic acid
US7264929B2 (en) 1999-09-16 2007-09-04 454 Life Sciences Corporation Method of sequencing a nucleic acid
US20030148344A1 (en) * 1999-09-16 2003-08-07 Rothberg Jonathan M. Method of sequencing a nucleic acid
US7244559B2 (en) 1999-09-16 2007-07-17 454 Life Sciences Corporation Method of sequencing a nucleic acid
US20040248161A1 (en) * 1999-09-16 2004-12-09 Rothberg Jonathan M. Method of sequencing a nucleic acid
US20030100102A1 (en) * 1999-09-16 2003-05-29 Rothberg Jonathan M. Apparatus and method for sequencing a nucleic acid
US20050119473A1 (en) * 2000-03-17 2005-06-02 Affymetrix, Inc. Phosphite ester oxidation in nucleic acid array preparation
US20070037187A1 (en) * 2000-03-24 2007-02-15 Isabelle Alexandre Identification and quantification of a plurality of biological (micro)organisms or their components
US7205104B2 (en) 2000-03-24 2007-04-17 Eppendorf Array Technologies Sa (Eat) Identification of biological (micro) organisms by detection of their homologous nucleotide sequences on arrays
US7202026B2 (en) * 2000-03-24 2007-04-10 Eppendorf Array Technologies Sa (Eat) Identification of a large number of biological (micro)organisms groups at different levels by their detection on a same array
US20030198943A1 (en) * 2000-03-24 2003-10-23 Jose Remacle Identification of a large number of biological (micro)organisms groups at different levels by their detection on a same array
US7829313B2 (en) 2000-03-24 2010-11-09 Eppendorf Array Technologies Identification and quantification of a plurality of biological (micro)organisms or their components
US7875442B2 (en) 2000-03-24 2011-01-25 Eppendorf Array Technologies Identification and quantification of a plurality of biological (micro)organisms or their components
US20020106646A1 (en) * 2000-03-24 2002-08-08 Jose Remacle Identification of biological (micro) organisms by detection of their homologous nucleotide sequences on arrays
US20080085515A1 (en) * 2000-03-24 2008-04-10 Eppendorf Array Technologies Sa (Eat) Identification of multiple biological (micro) organisms by detection of their nucleotide sequences on arrays
US20030059804A1 (en) * 2000-05-12 2003-03-27 Genemaster Lifescience Co., Ltd. Method for producing micro-carrier and test method by using said micro-carrier
US20030157528A1 (en) * 2000-06-14 2003-08-21 Jose Remacle Reverse detection for identification and/or quantification of nucleotide target sequences on biochips
US20020164634A1 (en) * 2000-08-26 2002-11-07 Perlegen Sciences, Inc. Methods for reducing complexity of nucleic acid samples
US20020168648A1 (en) * 2000-08-31 2002-11-14 Nobuko Yamamoto Method for analyzing base sequence of nucleic acid
US7273697B2 (en) * 2000-08-31 2007-09-25 Canon Kabushiki Kaisha Method for analyzing base sequence of nucleic acid
US20080051293A1 (en) * 2000-08-31 2008-02-28 Canon Kabushiki Kaisha Method for analyzing base sequence of nucleic acid
WO2002042485A3 (fr) * 2000-11-21 2003-02-06 Affymetrix Inc Procedes et progiciels permettant de choisir des sondes d'acides nucleiques
WO2002042485A2 (fr) * 2000-11-21 2002-05-30 Affymetrix, Inc. Procedes et progiciels permettant de choisir des sondes d'acides nucleiques
US7280922B2 (en) 2001-01-11 2007-10-09 Affymetrix, Inc. System, method, and computer software for genotyping analysis and identification of allelic imbalance
US20050250151A1 (en) * 2001-01-11 2005-11-10 Affymetrix, Inc. System, method, and computer software for genotyping analysis and identification of allelic imbalance
US6988040B2 (en) 2001-01-11 2006-01-17 Affymetrix, Inc. System, method, and computer software for genotyping analysis and identification of allelic imbalance
US20020110828A1 (en) * 2001-01-12 2002-08-15 Ferea Tracy L. Methods and compositions for microarray control
US6905826B2 (en) * 2001-01-12 2005-06-14 Applera Corporation Methods and compositions for microarray control
US20030082569A1 (en) * 2001-03-13 2003-05-01 Johnson Clayton H. Histoplasma capsulatum catalase sequences and their use in the detection of Histoplasma capsulatum and Histoplasmosis
US7052837B2 (en) 2001-03-13 2006-05-30 The Board Of Trustees Of The University Of Arkansas Histoplasma capsulatum catalase sequences and their use in the detection of Histoplamsa capsulatum and histoplasmosis
US7552013B2 (en) 2001-03-22 2009-06-23 Ge Healthcare Bio-Sciences Ab Ratio-based oligonucleotide probe selection
US20030027149A1 (en) * 2001-03-22 2003-02-06 David Dorris Ratio-based oligonucleotide probe selection
US7047141B2 (en) 2001-03-22 2006-05-16 Ge Healthcare Bio-Sciences Ab Ratio-based oligonucleotide probe selection
US20060155484A1 (en) * 2001-03-22 2006-07-13 Ge Healthcare Bio-Sciences Ab Ratio-based oligonucleotide probe selection
US20020160401A1 (en) * 2001-03-29 2002-10-31 Yasuyuki Nozaki Biochip and method of designing probes
US20110020815A1 (en) * 2001-03-30 2011-01-27 Nila Patil Methods for genomic analysis
US20050272086A1 (en) * 2001-03-30 2005-12-08 Perlegen Sciences, Inc. Methods for genomic analysis
US6969589B2 (en) 2001-03-30 2005-11-29 Perlegen Sciences, Inc. Methods for genomic analysis
US11031098B2 (en) 2001-03-30 2021-06-08 Genetic Technologies Limited Computer systems and methods for genomic analysis
US20030099964A1 (en) * 2001-03-30 2003-05-29 Perlegen Sciences, Inc. Methods for genomic analysis
US7035738B2 (en) * 2001-05-29 2006-04-25 Hitachi Sofware Engineering Co., Ltd. Probe designing apparatus and probe designing method
US20030069701A1 (en) * 2001-05-29 2003-04-10 Toshiko Matsumoto Probe designing apparatus and probe designing method
US20020187490A1 (en) * 2001-06-07 2002-12-12 Michigan State University Microbial identification chip based on DNA-DNA hybridization
WO2002101094A1 (fr) * 2001-06-07 2002-12-19 Michigan State University Puce d'identification microbienne fonctionnant sur le principe de l'hybridation adn-adn
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
AU2002323213B2 (en) * 2001-08-16 2008-03-13 Stratagene California Compositions and methods comprising control nucleic acid
US20030113762A1 (en) * 2001-08-17 2003-06-19 Warrington Janet A. Gleason grade 4/5 prostate cancer genes
US20050123913A1 (en) * 2001-08-30 2005-06-09 Emory University Human mitochondrial dna polymorphisms, haplogroups, associations with physiological conditions, and genotyping arrays
US20060099578A1 (en) * 2001-08-30 2006-05-11 Wallace Douglas C Mitochondrial biology expression arrays
US6902894B2 (en) * 2001-09-07 2005-06-07 Genetel Pharmaceuticals Ltd. Mutation detection on RNA polmerase beta subunit gene having rifampin resistance
US7326532B2 (en) 2001-09-18 2008-02-05 Gen-Probe Incorporated Detection of rpoB sequences of mycobacterium tuberculosis
US7094542B2 (en) 2001-09-18 2006-08-22 Gen-Probe Incorporated Detection of rpoB sequences of Mycobacterium tuberculosis
US20030108921A1 (en) * 2001-09-18 2003-06-12 Jucker Markus T. Detection of rpoB sequences of Mycobacterium tuberculosis
US20060263823A1 (en) * 2001-09-18 2006-11-23 Gen-Probe Incorporated Detection rpoB sequences of Mycobacterium Tuberculosis
US7326533B2 (en) 2001-09-18 2008-02-05 Gen-Probe Incorporated Detection rpoB sequences of Mycobacterium tuberculosis
US20060141493A1 (en) * 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
EP1453973A4 (fr) * 2001-12-11 2005-04-13 Affymetrix Inc Methodes de determination d'une activite transcriptionnelle
US20030157529A1 (en) * 2001-12-11 2003-08-21 Affymetrix, Inc. Methods for determining transcriptional activity
EP1453973A1 (fr) * 2001-12-11 2004-09-08 Affymetrix, Inc. Methodes de determination d'une activite transcriptionnelle
US6897025B2 (en) 2002-01-07 2005-05-24 Perlegen Sciences, Inc. Genetic analysis systems and methods
US20030157488A1 (en) * 2002-01-07 2003-08-21 Perlegen Sciences, Inc. Genetic analysis systems and methods
US20040053264A1 (en) * 2002-02-01 2004-03-18 Park Sung Sup Clinical panel assay using DNA chips
US7499806B2 (en) 2002-02-14 2009-03-03 Illumina, Inc. Image processing in microsphere arrays
US20030224383A1 (en) * 2002-04-23 2003-12-04 Mike West Atherosclerotic phenotype determinative genes and methods for using the same
US8383342B2 (en) 2002-04-24 2013-02-26 The University Of North Carolina At Greensboro Compositions, products, methods and systems to monitor water and other ecosystems
US9126165B1 (en) 2002-04-24 2015-09-08 The University Of North Carolina At Greensboro Nucleic acid arrays to monitor water and other ecosystems
US8048623B1 (en) 2002-04-24 2011-11-01 The University Of North Carolina At Greensboro Compositions, products, methods and systems to monitor water and other ecosystems
US7214492B1 (en) 2002-04-24 2007-05-08 The University Of North Carolina At Greensboro Nucleic acid arrays to monitor water and other ecosystems
US20040157238A1 (en) * 2002-09-20 2004-08-12 Quinn John J. Method for detection of multiple nucleic acid sequence variations
US7217519B1 (en) 2002-11-21 2007-05-15 The Board Of Trustees Of The University Of Arkansas Histoplasma capsulatum chitin synthase sequences and their use for detection of Histoplasma capsulatum and histoplasmosis
EP1447454A1 (fr) * 2003-02-14 2004-08-18 DR. Chip Biotechnology Incorporation Procédé et appareil pour détecter des pathogènes
CN100392098C (zh) * 2003-02-14 2008-06-04 晶宇生物科技实业股份有限公司 微阵列生物芯片的反射式图像获取装置与分析方法
US20090124514A1 (en) * 2003-02-26 2009-05-14 Perlegen Sciences, Inc. Selection probe amplification
US20080206743A1 (en) * 2003-05-16 2008-08-28 Mark Barbour Rapid and Specific Detection of Enterobacter Sakazakii
US20050032102A1 (en) * 2003-07-22 2005-02-10 Affymetrix, Inc. Mapping genomic rearrangements
US20050100911A1 (en) * 2003-08-06 2005-05-12 Perlegen Sciences, Inc. Methods for enriching populations of nucleic acid samples
US20050239104A1 (en) * 2003-11-04 2005-10-27 Ferea Tracy L Microarray controls
WO2005078131A1 (fr) * 2004-02-11 2005-08-25 Health Protection Agency Dosage de resistance a tb
US20100273146A1 (en) * 2004-02-11 2010-10-28 Timothy Brown TB resistance assay
US20070292860A1 (en) * 2004-04-29 2007-12-20 Schuren Frank H J Staphylococcus Aureus Specific Diagnostics
EP1595958A1 (fr) * 2004-05-10 2005-11-16 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Array specifique de Staphylococcus Aureus et Diagnostiques
US7338763B2 (en) 2004-06-02 2008-03-04 Eppendorf Array Technologies S.A. Method and kit for the detection and/or quantification of homologous nucleotide sequences on arrays
EP1602735A2 (fr) * 2004-06-02 2005-12-07 Eppendorf Array Technologies S.A. Méthode et kit de détection et/ou de quantification de séquences nucléotidiques homologues sur un réseau
EP1602735A3 (fr) * 2004-06-02 2006-10-25 Eppendorf Array Technologies S.A. Méthode et kit de détection et/ou de quantification de séquences nucléotidiques homologues sur un réseau
US20050272044A1 (en) * 2004-06-02 2005-12-08 Jose Remacle Method and kit for the detection and/or quantification of homologous nucleotide sequences on arrays
JP2008503222A (ja) * 2004-06-18 2008-02-07 ニンブルゲン システムズ インコーポレイテッド 可変長プローブ選択
AU2005258180B2 (en) * 2004-06-18 2009-10-29 Nimblegen Systems, Inc. Variable length probe selection
WO2006002281A1 (fr) 2004-06-18 2006-01-05 Nimblegen Systems, Inc. Selection de sondes a longueur variable
US20050282209A1 (en) * 2004-06-18 2005-12-22 Thomas Albert Variable length probe selection
US7636637B2 (en) 2004-06-18 2009-12-22 Roche Nimblegen, Inc. Variable length probe selection
AU2005327520B2 (en) * 2004-07-02 2011-04-28 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Resequencing pathogen microarray
US9430610B2 (en) * 2004-07-02 2016-08-30 The United States Of America, As Represented By The Secretary Of The Navy Re-sequencing pathogen microarray
EP1778881A2 (fr) * 2004-07-02 2007-05-02 The Government of the United States of America as represented by The Secretary of the Navy Resequençage de microreseau de pathogenes
US20090170717A1 (en) * 2004-07-02 2009-07-02 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Re-sequencing pathogen microarray
US20060210967A1 (en) * 2004-07-02 2006-09-21 Agan Brian K Re-sequencing pathogen microarray
EP1778881A4 (fr) * 2004-07-02 2008-12-10 Us Gov Sec Navy Resequençage de microreseau de pathogenes
US20060051769A1 (en) * 2004-09-03 2006-03-09 Affymetrix, Inc. Methods of genetic analysis of E. coli
US7323308B2 (en) 2004-09-03 2008-01-29 Affymetrix, Inc. Methods of genetic analysis of E. coli
US20060166224A1 (en) * 2005-01-24 2006-07-27 Norviel Vernon A Associations using genotypes and phenotypes
US20100113295A1 (en) * 2005-01-24 2010-05-06 Norviel Vernon A Associations Using Genotypes and Phenotypes
US20060183132A1 (en) * 2005-02-14 2006-08-17 Perlegen Sciences, Inc. Selection probe amplification
EP1693470A1 (fr) 2005-02-15 2006-08-23 Agilent Technologies, Inc. Méthodes et compositions pour la détermination de la cytotoxicité d'agents de transfection
US20090215634A1 (en) * 2005-03-11 2009-08-27 Sven Bulow Microarray with temperature specific controls
WO2006094794A1 (fr) * 2005-03-11 2006-09-14 Eppendorf Ag Micromatrice avec commandes spécifiques de température
EP2604703A2 (fr) 2005-03-14 2013-06-19 The Board of Trustees of Leland Stanford Junior University Procédés permettant d'évaluer la survie d'un greffon chez un destinataire d'une transplantation d'organe solide
US20090264307A1 (en) * 2006-01-13 2009-10-22 The Trustees Of Princeton University Array-based polymorphism mapping at single nucleotide resolution
US8055098B2 (en) 2006-01-27 2011-11-08 Affymetrix, Inc. System, method, and product for imaging probe arrays with small feature sizes
US20070197911A1 (en) * 2006-01-27 2007-08-23 Affymetrix, Inc. System, Method, and Product for Imaging Probe Arrays with Small Feature Sizes
US9445025B2 (en) 2006-01-27 2016-09-13 Affymetrix, Inc. System, method, and product for imaging probe arrays with small feature sizes
US8520976B2 (en) 2006-01-27 2013-08-27 Affymetrix, Inc. System, method, and product for imaging probe arrays with small feature size
US9528939B2 (en) 2006-03-10 2016-12-27 Indx Lifecare, Inc. Waveguide-based optical scanning systems
US7951583B2 (en) 2006-03-10 2011-05-31 Plc Diagnostics, Inc. Optical scanning system
US10590493B2 (en) 2006-03-10 2020-03-17 Ldip, Llc Waveguide-based detection system with scanning light source
US9423397B2 (en) 2006-03-10 2016-08-23 Indx Lifecare, Inc. Waveguide-based detection system with scanning light source
US20100302544A1 (en) * 2006-03-10 2010-12-02 Reuven Duer Waveguide-based detection system with scanning light source
US8187866B2 (en) 2006-03-10 2012-05-29 Plc Diagnostics, Inc. Optical scanning system
US10551318B2 (en) 2006-03-10 2020-02-04 Ldip, Llc Waveguide-based optical scanning systems
US9976192B2 (en) 2006-03-10 2018-05-22 Ldip, Llc Waveguide-based detection system with scanning light source
US20070211985A1 (en) * 2006-03-10 2007-09-13 Plc Diagnostics, Inc. Optical Scanning System
US8675199B2 (en) 2006-03-10 2014-03-18 Plc Diagnostics, Inc. Waveguide-based detection system with scanning light source
US20090291858A1 (en) * 2006-11-30 2009-11-26 The Regents Of The University Of California Array for detecting microbes
US8771940B2 (en) 2006-11-30 2014-07-08 The Regents Of The University Of California Array for detecting microbes
EP2993473A1 (fr) 2007-01-30 2016-03-09 Pharmacyclics, Inc. Procédés permettant de déterminer la résistance du cancer aux inhibiteurs de l'histone désacétylase
US20080287308A1 (en) * 2007-05-18 2008-11-20 Affymetrix, Inc. System, method, and computer software product for genotype determination using probe array data
US10832796B2 (en) 2007-05-18 2020-11-10 Affymetrix, Inc. System, method, and computer software product for genotype determination using probe array data
US9760675B2 (en) 2007-05-18 2017-09-12 Affymetrix, Inc. System, method, and computer software product for genotype determination using probe array data
US8200440B2 (en) 2007-05-18 2012-06-12 Affymetrix, Inc. System, method, and computer software product for genotype determination using probe array data
US8883691B2 (en) 2007-06-25 2014-11-11 Affymetrix, Inc. Encoded microparticles
US20090149340A1 (en) * 2007-06-25 2009-06-11 True Materials, Inc. Encoded microparticles
US20090068668A1 (en) * 2007-09-12 2009-03-12 Plc Diagnostics, Inc. Waveguide-Based Optical Scanning Systems
US8288157B2 (en) 2007-09-12 2012-10-16 Plc Diagnostics, Inc. Waveguide-based optical scanning systems
US8747751B2 (en) 2008-06-16 2014-06-10 Plc Diagnostics, Inc. System and method for nucleic acids sequencing by phased synthesis
EP2631301A1 (fr) 2008-08-18 2013-08-28 The Board of Trustees of the Leland Stanford Junior University Procédés et compositions pour déterminer un phénotype tolérant à une greffe chez un sujet
US9329170B2 (en) 2009-01-20 2016-05-03 The Board Of Trustees Of The Leland Stanford Junior University Single cell gene expression for diagnosis, prognosis and identification of drug targets
US20100255471A1 (en) * 2009-01-20 2010-10-07 Stanford University Single cell gene expression for diagnosis, prognosis and identification of drug targets
WO2010107825A2 (fr) 2009-03-16 2010-09-23 Pangu Biopharma Limited Compositions et procedes comprenant des variants d'epissage d'histidyl-arnt synthetase presentant des activites biologiques non canoniques
EP3255146A1 (fr) 2009-03-16 2017-12-13 Pangu Biopharma Limited Compositions et procedes comprenant des variants d'epissage d'histidyl-arnt synthetase presentant des activites biologiques non canoniques
WO2010120509A2 (fr) 2009-03-31 2010-10-21 Atyr Pharma, Inc. Compositions et procédés impliquant des aspartyl-arnt synthétases présentant des activités biologiques non canoniques
EP3185013A2 (fr) 2009-12-02 2017-06-28 The Board of Trustees of the Leland Stanford Junior University Biomarqueurs pour déterminer un xénotype tolérant à l'allogreffe
EP2803735A1 (fr) 2010-03-25 2014-11-19 The Board Of Trustees Of The Leland Stanford Junior University Biomarqueurs de protéines et de gènes pour le rejet d'organes transplantés
WO2011139714A2 (fr) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps se rapportant à des fragments protéiques de la cystéinyl-arnt synthétase
WO2011139799A2 (fr) 2010-04-27 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps se rapportant à des fragments protéiques d'isoleucyl arnt synthétases
WO2011139853A2 (fr) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Compositions thérapeutiques, diagnostiques et d'anticorps à base de fragments de protéines d'aminoacyl-arnt synthétases
WO2011135459A2 (fr) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Méthodes et dispositifs permettant de prédire l'efficacité d'un traitement
WO2011139854A2 (fr) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à based'anticorps associées à des fragments protéiques d'asparaginyl-arnt-synthétases
WO2011139907A2 (fr) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Découverte innovatrice de compositions thérapeutiques, diagnostiques, et d'anticorps associées aux fragments protéiques des valyle arnt synthésases
WO2011140132A2 (fr) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de phénylalanyl-alpha-arnt-synthétases
WO2011140135A2 (fr) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées des fragments protéiques de méthionyl-arnt-synthétases
WO2011139986A2 (fr) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à des fragments protéiques d'arginyle-arnt synthétases
WO2011140267A2 (fr) 2010-05-04 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de complexe multi-arnt synthétase p38
WO2011143482A2 (fr) 2010-05-14 2011-11-17 Atyr Pharma, Inc. Découverte de compositions inédites de nature thérapeutique, diagnostique et à base d'anticorps contenant des fragments protéiques de phénylalanyl-bêta-arnt synthétases
WO2011146410A2 (fr) 2010-05-17 2011-11-24 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic, et d'anticorps associées à des fragments protéiques de leucyl-arnt synthétases
WO2011150279A2 (fr) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à fragments protéiques de glutaminyl-arnt synthétases
WO2011153277A2 (fr) 2010-06-01 2011-12-08 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques, et d'anticorps associés à des fragments de protéine de lysyl-tarn synthétases
WO2012021247A2 (fr) 2010-07-12 2012-02-16 Atyr Pharma, Inc. DÉCOUVERTE INNOVANTE DE COMPOSITIONS THÉRAPEUTIQUES, DE DIAGNOSTIC ET D'ANTICORPS SE RAPPORTANT À DES FRAGMENTS PROTÉIQUES DE GLYCYL-ARNt SYNTHÉTASES
WO2012027611A2 (fr) 2010-08-25 2012-03-01 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et d'anticorps associées à des fragments protéiniques des tyrosyl-arnt synthétases
US10378066B2 (en) 2010-09-15 2019-08-13 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
US10214777B2 (en) 2010-09-15 2019-02-26 Almac Diagnostics Limited Molecular diagnostic test for cancer
US9677140B2 (en) 2010-09-15 2017-06-13 Almac Diagonostics Limited Molecular diagnostic test for cancer
WO2012037378A2 (fr) 2010-09-15 2012-03-22 Almac Diagnostics Limited Test de diagnostic moléculaire du cancer
EP2975399A1 (fr) 2010-09-15 2016-01-20 Almac Diagnostics Limited Test de diagnostic moléculaire pour le cancer
WO2012163541A1 (fr) 2011-06-01 2012-12-06 Medical Prognosis Institute A/S Procédés et dispositifs pour le pronostic d'une rechute du cancer
EP3311847A1 (fr) 2012-02-16 2018-04-25 Atyr Pharma, Inc. Histidyl-arnt synthétases pour le traitement de maladies auto-immunes et inflammatoires
WO2013123432A2 (fr) 2012-02-16 2013-08-22 Atyr Pharma, Inc. Histidyl-arnt synthétases pour le traitement de maladies auto-immunes et inflammatoires
WO2014085434A1 (fr) 2012-11-27 2014-06-05 Pontificia Universidad Catolica De Chile Compositions et procédés de diagnostic de tumeurs de la thyroïde
WO2014148780A1 (fr) 2013-03-20 2014-09-25 서울대학교산학협력단 Biomarqueur pour le diagnostic du cancer du foie
WO2014195032A1 (fr) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Procédés et dispositifs pour prédire une efficacité de traitement de fulvestrant chez des patients atteints de cancer
WO2015023068A1 (fr) 2013-08-13 2015-02-19 서울대학교산학협력단 Procédé de criblage de marqueur de cancer par l'intermédiaire d'une détection de déglycosylation de glycoprotéine et de marqueur de cancer hépatocellulaire
US10018566B2 (en) 2014-02-28 2018-07-10 Ldip, Llc Partially encapsulated waveguide based sensing chips, systems and methods of use
WO2016008048A1 (fr) 2014-07-15 2016-01-21 Ontario Institute For Cancer Research Procédés et dispositifs permettant de prédire l'efficacité d'un traitement à l'anthracycline
US20160083793A1 (en) * 2014-08-19 2016-03-24 Joshua Labaer Radiation biodosimetry systems
US10435747B2 (en) * 2014-08-19 2019-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Radiation biodosimetry systems
US10787710B2 (en) 2014-08-19 2020-09-29 Arizona Board Of Regents On Behalf Of Arizona State University Radiation biodosimetry systems
US11181479B2 (en) 2015-02-27 2021-11-23 Ldip, Llc Waveguide-based detection system with scanning light source
WO2017013436A1 (fr) 2015-07-21 2017-01-26 Almac Diagnostics Limited Signature génique pour immunothérapies dans le cancer
WO2017181367A1 (fr) 2016-04-20 2017-10-26 Ldx Prognostics Limited Co. Procédés et compositions pour pronostiquer une naissance prématurée
WO2017197573A1 (fr) 2016-05-17 2017-11-23 Ldx Prognostics Limited Co. Méthodes et compositions pour fournir une évaluation de la prééclampsie
WO2018208091A2 (fr) 2017-05-10 2018-11-15 서울대학교산학협력단 Biomarqueur permettant de surveiller ou de diagnostiquer l'apparition d'un cancer du foie dans un groupe fortement exposé à un cancer du foie et son utilisation

Also Published As

Publication number Publication date
EP0937159A1 (fr) 1999-08-25
JP2000504575A (ja) 2000-04-18
EP0937159A4 (fr) 2004-10-20
AU2189397A (en) 1997-08-28
WO1997029212A1 (fr) 1997-08-14

Similar Documents

Publication Publication Date Title
US6228575B1 (en) Chip-based species identification and phenotypic characterization of microorganisms
US7252948B2 (en) Chip-based speciation and phenotypic characterization of microorganisms
EP1124990B1 (fr) Gestion de la complexite et analyse d'adn genomique
US7205104B2 (en) Identification of biological (micro) organisms by detection of their homologous nucleotide sequences on arrays
US20060199183A1 (en) Probe biochips and methods for use thereof
US8119788B2 (en) Compositions and methods for the detection of Candida species
Wiid et al. Oligonucleotide (GTG) 5 as a marker for Mycobacterium tuberculosis strain identification
EP0951569A2 (fr) Micropuces oligonucleotidiques sur mesure utilisees comme capteurs multiples
NZ521626A (en) Methods for genotyping by hybridization analysis
EP0652971A4 (fr) Systeme de detection de gene.
EP1096024A1 (fr) Méthode et trousse pour le criblage et/ou la quantification de séquences d' acides nucléiques multiples homologues avec des ensembles de sondes
AU2001270504A1 (en) Novel assay for nucleic acid analysis
JP2002525127A (ja) 遺伝子型決定およびｄｎａ分析に関する、方法および生成物
WO2006097233A2 (fr) Determination de la resistance aux antibiotiques du staphylocoque dore
EP0967291A1 (fr) Méthode de criblage parallèle de variations alléliques
US7592135B2 (en) High resolution typing system for pathogenic Mycobacterium tuberculosum
EP1728875A2 (fr) Spéciation de micro-organismes à partir de micro plaquettes et caractérisation des phénotypes de ceux-ci
WO1999058721A1 (fr) Amplification muliplex d'adn a l'aide d'amorces chimeres
WO2009121091A1 (fr) Procédés de mappage pour des sujets polyploïdes
AU777140B2 (en) Molecular markers in clovers
Carter et al. Array-CGH for the Analysis of Constitutional Genomic Rearrangements
AU2005200014A1 (en) Molecular markers in clovers

Legal Events

Date Code Title Description
AS Assignment

Owner name: AFFYMETRIX, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GINGERAS, THOMAS R.;MACK, DAVID;CHEE, MARK S.;AND OTHERS;REEL/FRAME:008629/0363;SIGNING DATES FROM 19970619 TO 19970702

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT, MA

Free format text: SECURITY AGREEMENT;ASSIGNOR:AFFYMETRIX, INC.;REEL/FRAME:028465/0541

Effective date: 20120625

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT, TE

Free format text: SECURITY INTEREST;ASSIGNOR:AFFYMETRIX, INC.;REEL/FRAME:036988/0166

Effective date: 20151028

AS Assignment

Owner name: AFFYMETRIX, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT;REEL/FRAME:037109/0132

Effective date: 20151028

AS Assignment

Owner name: AFFYMETRIX, INC., CALIFORNIA

Free format text: NOTICE OF RELEASE;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:038361/0891

Effective date: 20160328